CN111587239A - 内酰胺化合物的制造方法及由其制造的内酰胺化合物 - Google Patents
内酰胺化合物的制造方法及由其制造的内酰胺化合物 Download PDFInfo
- Publication number
- CN111587239A CN111587239A CN201980007242.4A CN201980007242A CN111587239A CN 111587239 A CN111587239 A CN 111587239A CN 201980007242 A CN201980007242 A CN 201980007242A CN 111587239 A CN111587239 A CN 111587239A
- Authority
- CN
- China
- Prior art keywords
- chemical formula
- alkyl
- hydrogen
- lactam compound
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 lactam compound Chemical class 0.000 title claims abstract description 256
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 128
- 239000003054 catalyst Substances 0.000 claims abstract description 64
- 239000000126 substance Substances 0.000 claims description 123
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 65
- 229910052739 hydrogen Inorganic materials 0.000 claims description 57
- 239000001257 hydrogen Substances 0.000 claims description 57
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 150000002367 halogens Chemical group 0.000 claims description 41
- 125000006736 (C6-C20) aryl group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 150000002431 hydrogen Chemical class 0.000 claims description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000002723 alicyclic group Chemical group 0.000 claims description 17
- 229910052741 iridium Inorganic materials 0.000 claims description 15
- 230000002862 amidating effect Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000007112 amidation reaction Methods 0.000 claims description 10
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical group [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims description 9
- 229910001494 silver tetrafluoroborate Inorganic materials 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910001544 silver hexafluoroantimonate(V) Inorganic materials 0.000 claims description 6
- 230000009435 amidation Effects 0.000 claims description 5
- HSYLTRBDKXZSGS-UHFFFAOYSA-N silver;bis(trifluoromethylsulfonyl)azanide Chemical compound [Ag+].FC(F)(F)S(=O)(=O)[N-]S(=O)(=O)C(F)(F)F HSYLTRBDKXZSGS-UHFFFAOYSA-N 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000010948 rhodium Chemical group 0.000 claims description 4
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 claims description 4
- 229910017744 AgPF6 Inorganic materials 0.000 claims description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 3
- 229910017052 cobalt Chemical group 0.000 claims description 3
- 239000010941 cobalt Chemical group 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical group [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 229910052703 rhodium Inorganic materials 0.000 claims description 3
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical group [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 3
- 229910052707 ruthenium Inorganic materials 0.000 claims description 3
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 claims description 2
- 125000003860 C1-C20 alkoxy group Chemical group 0.000 claims 11
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims 7
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 125000005545 phthalimidyl group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 26
- 239000007858 starting material Substances 0.000 abstract description 20
- 239000003446 ligand Substances 0.000 abstract description 5
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 abstract description 2
- 239000004711 α-olefin Substances 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 253
- 239000007787 solid Substances 0.000 description 138
- 238000005160 1H NMR spectroscopy Methods 0.000 description 75
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 74
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- 238000002360 preparation method Methods 0.000 description 29
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 27
- 125000003545 alkoxy group Chemical group 0.000 description 21
- 125000001072 heteroaryl group Chemical group 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 11
- UXNFKHPENVDGBG-UHFFFAOYSA-N deca-6,9-diene-2,8-dione Chemical compound CC(CCCC=CC(C=C)=O)=O UXNFKHPENVDGBG-UHFFFAOYSA-N 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 9
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 8
- 229960001171 acetohydroxamic acid Drugs 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- SSYBQSNJYJMEKD-UHFFFAOYSA-N COC=1C=C2CC(NC2=CC1)=O.COC=1C=C2CC(NC2=CC1)=O Chemical compound COC=1C=C2CC(NC2=CC1)=O.COC=1C=C2CC(NC2=CC1)=O SSYBQSNJYJMEKD-UHFFFAOYSA-N 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- DQRFCVHLNUNVPL-UHFFFAOYSA-N 2h-1,3-oxazol-5-one Chemical compound O=C1OCN=C1 DQRFCVHLNUNVPL-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- BRAMFOXPHQBGRC-UHFFFAOYSA-N OC1=CC=C(C=C1)CCC1=NOC(O1)=O Chemical compound OC1=CC=C(C=C1)CCC1=NOC(O1)=O BRAMFOXPHQBGRC-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 125000005544 phthalimido group Chemical group 0.000 description 6
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- VIXWGKYSYIBATJ-UHFFFAOYSA-N pyrrol-2-one Chemical compound O=C1C=CC=N1 VIXWGKYSYIBATJ-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- WLRCRKKKFFPSPD-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)-2-oxoacetic acid Chemical compound C1=CC=C2OC(CNC(=O)C(=O)O)COC2=C1 WLRCRKKKFFPSPD-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- FPDLUAACCNVSQA-UHFFFAOYSA-N 7-chloro-1,3-dihydroindol-2-one Chemical compound ClC1=CC=CC2=C1NC(=O)C2 FPDLUAACCNVSQA-UHFFFAOYSA-N 0.000 description 3
- APQCUXBFROFCOM-UHFFFAOYSA-N 7-methoxy-1,3-dihydroindol-2-one Chemical compound COC1=CC=CC2=C1NC(=O)C2 APQCUXBFROFCOM-UHFFFAOYSA-N 0.000 description 3
- FRVJKZDEBVYRGZ-UHFFFAOYSA-N 8-bromo-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=C1C=CC=C2Br FRVJKZDEBVYRGZ-UHFFFAOYSA-N 0.000 description 3
- ILTWLOPILDYCKW-UHFFFAOYSA-N 8-methoxy-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=C1C=CC=C2OC ILTWLOPILDYCKW-UHFFFAOYSA-N 0.000 description 3
- NCQOEKMWICFEHS-UHFFFAOYSA-N 8-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=C1C=CC=C2C NCQOEKMWICFEHS-UHFFFAOYSA-N 0.000 description 3
- JZLNMCGKKHXZMI-UHFFFAOYSA-N B(O)(O)O.FC(C=1C=C(C=C(C1)C(F)(F)F)[Na])(F)F Chemical compound B(O)(O)O.FC(C=1C=C(C=C(C1)C(F)(F)F)[Na])(F)F JZLNMCGKKHXZMI-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 125000003556 N-methyl-L-phenylalanine group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- WDFKMLRRRCGAKS-UHFFFAOYSA-N chloroxine Chemical compound C1=CN=C2C(O)=C(Cl)C=C(Cl)C2=C1 WDFKMLRRRCGAKS-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- KAVKNHPXAMTURG-UHFFFAOYSA-N n-(4-bromonaphthalen-1-yl)acetamide Chemical compound C1=CC=C2C(NC(=O)C)=CC=C(Br)C2=C1 KAVKNHPXAMTURG-UHFFFAOYSA-N 0.000 description 3
- 125000000962 organic group Chemical group 0.000 description 3
- 125000002097 pentamethylcyclopentadienyl group Chemical group 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical group C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 2
- IZYNXIGQFJREMT-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1.C1=CC=C2NC(=O)CCC2=C1 IZYNXIGQFJREMT-UHFFFAOYSA-N 0.000 description 2
- NZCLXHVUAXJXIR-UHFFFAOYSA-N 3-(2-bromopropanoyl)-1,3-benzoxazol-2-one Chemical compound C1=CC=C2OC(=O)N(C(=O)C(Br)C)C2=C1 NZCLXHVUAXJXIR-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- 125000001750 3-nitrocinnamoyl group Chemical group 0.000 description 2
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- STQUCJZSEVAMPY-UHFFFAOYSA-N 5-hydroxy-6-methoxy-2-methylisoindole-1,3-dione Chemical compound C1=C(O)C(OC)=CC2=C1C(=O)N(C)C2=O STQUCJZSEVAMPY-UHFFFAOYSA-N 0.000 description 2
- QOGPNCUTXVZQSL-UHFFFAOYSA-N 6,7-dimethoxy-1h-quinolin-4-one Chemical compound C1=CC(O)=C2C=C(OC)C(OC)=CC2=N1 QOGPNCUTXVZQSL-UHFFFAOYSA-N 0.000 description 2
- FXSDFAGQQKKLSU-UHFFFAOYSA-N 7-bromo-1-azaspiro[4.5]deca-6,9-diene-2,8-dione Chemical compound BrC1=CC2(CCC(N2)=O)C=CC1=O FXSDFAGQQKKLSU-UHFFFAOYSA-N 0.000 description 2
- UAIKQUZQXSTAKX-UHFFFAOYSA-N 7-methyl-1,3-dihydroindol-2-one Chemical compound CC1=CC=CC2=C1NC(=O)C2 UAIKQUZQXSTAKX-UHFFFAOYSA-N 0.000 description 2
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229960003540 oxyquinoline Drugs 0.000 description 2
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- 125000006654 (C3-C12) heteroaryl group Chemical group 0.000 description 1
- ITWFKDWNQCKASQ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F.FC(F)(F)C(O)C(F)(F)F ITWFKDWNQCKASQ-UHFFFAOYSA-N 0.000 description 1
- YBXVYPWMLVCAQF-UHFFFAOYSA-N 1,1-dimethyl-3-quinolin-8-ylurea Chemical compound CN(C)C(=O)Nc1cccc2cccnc12 YBXVYPWMLVCAQF-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical class C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- FBBYMLLXCOVIJS-UHFFFAOYSA-N 1-azaspiro[4.5]deca-6,9-diene-2,8-dione Chemical compound O=C1CCC2(N1)C=CC(=O)C=C2 FBBYMLLXCOVIJS-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-MICDWDOJSA-N 1-deuteriopropan-2-one Chemical compound [2H]CC(C)=O CSCPPACGZOOCGX-MICDWDOJSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- ZFOCMWZKYXXLBD-UHFFFAOYSA-N 2,4-dimethylfuro[3,2-c]quinoline Chemical compound C1=CC=CC2=C(OC(C)=C3)C3=C(C)N=C21 ZFOCMWZKYXXLBD-UHFFFAOYSA-N 0.000 description 1
- GYIYKSJCEHPLHN-UHFFFAOYSA-N 2-(3-methylphenyl)acetic acid Chemical compound CC1=CC=CC(CC(O)=O)=C1.CC1=CC=CC(CC(O)=O)=C1 GYIYKSJCEHPLHN-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- LLPBUXODFQZPFH-UHFFFAOYSA-N 3,3-dimethyl-1h-benzo[g]indole-2,4,5-trione Chemical compound O=C1C(=O)C2=CC=CC=C2C2=C1C(C)(C)C(=O)N2 LLPBUXODFQZPFH-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- LBCLBBSEPLFROS-UHFFFAOYSA-N 3-(4-hydroxy-2-methoxyphenyl)-1,4,2-dioxazol-5-one Chemical compound OC1=CC(=C(C=C1)C1=NOC(O1)=O)OC LBCLBBSEPLFROS-UHFFFAOYSA-N 0.000 description 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
- LZBBEECOKDJNLB-UHFFFAOYSA-N 3-phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1.OC(=O)CCC1=CC=CC=C1 LZBBEECOKDJNLB-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- WWJLCYHYLZZXBE-UHFFFAOYSA-N 5-chloro-1,3-dihydroindol-2-one Chemical compound ClC1=CC=C2NC(=O)CC2=C1 WWJLCYHYLZZXBE-UHFFFAOYSA-N 0.000 description 1
- DFGZEOUBIHLXFD-UHFFFAOYSA-N 5-methoxy-1,3-dihydroindol-2-one Chemical compound COC1=CC=C2NC(=O)CC2=C1 DFGZEOUBIHLXFD-UHFFFAOYSA-N 0.000 description 1
- SNPPISFHRFQHLP-UHFFFAOYSA-N 5-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=C1C=CC=C2C SNPPISFHRFQHLP-UHFFFAOYSA-N 0.000 description 1
- XHKXYVRULOMTOW-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=CC(OC)=CC=C21 XHKXYVRULOMTOW-UHFFFAOYSA-N 0.000 description 1
- DKNXPCXIGGIJNY-UHFFFAOYSA-N 6-methyl-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=CC(C)=CC=C21 DKNXPCXIGGIJNY-UHFFFAOYSA-N 0.000 description 1
- SZZZZSAMIAZSIE-UHFFFAOYSA-N 8-chloro-2,3-dihydro-1h-quinolin-4-one Chemical compound O=C1CCNC2=C1C=CC=C2Cl SZZZZSAMIAZSIE-UHFFFAOYSA-N 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- HIAHNGLEMOOZEB-UHFFFAOYSA-N COC1=CC(C2(CCC(N2)=O)C=C1)=O Chemical compound COC1=CC(C2(CCC(N2)=O)C=C1)=O HIAHNGLEMOOZEB-UHFFFAOYSA-N 0.000 description 1
- CNMKOUYUSADQRU-UHFFFAOYSA-N COC=1C=C(C=CC1OC)CC(=O)O.C(C)(=O)O Chemical compound COC=1C=C(C=CC1OC)CC(=O)O.C(C)(=O)O CNMKOUYUSADQRU-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PJPXMALKXJDXTB-UHFFFAOYSA-N ClC=1C=C(C=CC1)CC(=O)O.ClC=1C=C(C=CC1)CC(=O)O Chemical compound ClC=1C=C(C=CC1)CC(=O)O.ClC=1C=C(C=CC1)CC(=O)O PJPXMALKXJDXTB-UHFFFAOYSA-N 0.000 description 1
- DKCXJWAUEUTXBE-UHFFFAOYSA-N ClC=1C=C2CC(NC2=CC1)=O.ClC=1C=C2CC(NC2=CC1)=O Chemical compound ClC=1C=C2CC(NC2=CC1)=O.ClC=1C=C2CC(NC2=CC1)=O DKCXJWAUEUTXBE-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- MNYARIILPGRTQL-WPRPVWTQSA-N Ephedroxane Chemical compound O1C(=O)N(C)[C@@H](C)[C@H]1C1=CC=CC=C1 MNYARIILPGRTQL-WPRPVWTQSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 125000002977 L-tyrosinyl radical cation group Chemical group 0.000 description 1
- IDSGFSCSMXRJON-UHFFFAOYSA-N N-Carbamyl-L-glutamicacid Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC1=CC=CC=C1 IDSGFSCSMXRJON-UHFFFAOYSA-N 0.000 description 1
- SLDILUBCEOALBP-UHFFFAOYSA-N N1C2(CCC1=O)C(C=CC1=CC=CC=C12)=O Chemical compound N1C2(CCC1=O)C(C=CC1=CC=CC=C12)=O SLDILUBCEOALBP-UHFFFAOYSA-N 0.000 description 1
- GSFAIDOXSGMCBL-UHFFFAOYSA-N O=C1N(C(C2=CC=CC=C12)=O)C1C(NC2(C1)C=CC(C=C2)=O)=O Chemical compound O=C1N(C(C2=CC=CC=C12)=O)C1C(NC2(C1)C=CC(C=C2)=O)=O GSFAIDOXSGMCBL-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- JHRWWRDRBPCWTF-OLQVQODUSA-N captafol Chemical compound C1C=CC[C@H]2C(=O)N(SC(Cl)(Cl)C(Cl)Cl)C(=O)[C@H]21 JHRWWRDRBPCWTF-OLQVQODUSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- CZKMPDNXOGQMFW-UHFFFAOYSA-N chloro(triethyl)germane Chemical compound CC[Ge](Cl)(CC)CC CZKMPDNXOGQMFW-UHFFFAOYSA-N 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000003950 cyclic amides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000003914 fluoranthenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC=C4C1=C23)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- LOZPDDOQLJRAQS-UHFFFAOYSA-N hydron;pyridin-3-yl furan-2-carboxylate;chloride Chemical compound Cl.C=1C=COC=1C(=O)OC1=CC=CN=C1 LOZPDDOQLJRAQS-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- AIRPJJGSWHWBKS-UHFFFAOYSA-N hydroxymethylphosphanium;chloride Chemical compound [Cl-].OC[PH3+] AIRPJJGSWHWBKS-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- YDWPOGYTJVQQIL-UHFFFAOYSA-N methyl 2-(4-aminophenoxy)acetate Chemical compound COC(=O)COC1=CC=C(N)C=C1 YDWPOGYTJVQQIL-UHFFFAOYSA-N 0.000 description 1
- TUQRZARLAYWDBD-UHFFFAOYSA-N methyl 5-bromo-2-(methylamino)benzoate Chemical compound CNC1=CC=C(Br)C=C1C(=O)OC TUQRZARLAYWDBD-UHFFFAOYSA-N 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- CFSCDGFNXLEISC-UHFFFAOYSA-N nona-5,8-diene-2,7-dione Chemical compound CC(CCC=CC(C=C)=O)=O CFSCDGFNXLEISC-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- YGSFNCRAZOCNDJ-UHFFFAOYSA-N propan-2-one Chemical compound CC(C)=O.CC(C)=O YGSFNCRAZOCNDJ-UHFFFAOYSA-N 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- MHKFWKVLUPCEAH-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1.C1=CN=C2C(O)=CC=CC2=C1 MHKFWKVLUPCEAH-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000003960 triphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C3=CC=CC=C3C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0073—Rhodium compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
本发明涉及在具有特定配体的催化剂存在下由二
Description
技术领域
本发明涉及内酰胺化合物及由其制造的内酰胺化合物,详细地,涉及利用特定的催化剂的内酰胺化合物的制造方法及由其制造的内酰胺化合物。
背景技术
将由石油或可再生生物质供应源中大量供应的附加值低的烃纯化成附加值高的化学物质的最优选方法是利用催化剂来氧化C-H键的反应。
因此,利用催化剂来氧化C-H键的反应被视为在化学中最重要的反应中的一种,并且利用催化剂的具有C-H键的脂肪族化合物的硝化反应是最常用于各种有机合成、药物和材料化学中的非常重要的反应。
用于实施C-N偶联反应的有效且常用的方法是在利用金属催化剂的C-H胺化反应中将亲核性氨基官能团转化为反应性更强的亲电子性氮烯。
这样的反应非常有效,因此许多研究人员对相关反应已经进行了很长时间的研究。
作为一个例子,由布雷斯洛(Breslow)等人公布了在用Fe(III)或Rh(II)催化的氧杂噻唑烷的合成中,作为反应性过氧化物的ROSO2N=IR'(iminoiodinanes,亚氨基碘烷)可以用作磺酰氮烯(sulfonylnitrene)前体,此后研究了与之相关的多种方法。
但是,C-H酰胺化在适用于在有机合成的原料、中间体和医药用途中非常有用的内酰胺之类的环状酰胺的制造时存在尚未解决的课题,其路径也不明确。
众所周知可以直接制造环状酰胺化合物的最简单的前体也是最重要的中间体是在原位(in-situ)反应中生成的羰基氮烯(carbonylnitrenes)。
因此,认为原则上利用金属的催化反应通过主要金属-氮烯中间体进行反应,接着插入C-H键,能够生成相应于此的氮杂杂环化合物。
但是,用C-H酰胺化反应无法合成内酰胺化合物的最主要的理由是被认为是中间体的金属-羰基氮烯中间体不稳定,因此通过克尔提斯(Curtius)类型的重排容易地生成异氰酸酯。
这样的不稳定性还可以通过光分解、热分解和过渡金属催化剂条件下的作为合成前体的酰基叠氮来说明。
因此,由于酰基叠氮不适合用作C-H酰胺化反应的供应源,需要特定的酰胺供应源,进而事实上也需要对于用于以优异的选择性和收率制造内酰胺化合物的催化剂的研究。
发明内容
本发明人努力解决如上所述的问题时,发现利用具有特定官能团的起始物质和具有特定配体的特定催化剂的组合可以以优异的选择性和收率制造内酰胺化合物,从而完成了本发明。
此外,本发明提供根据本发明的内酰胺化合物的制造方法而制造的内酰胺化合物。
本发明提供通过特定催化剂和特定起始物质的组合以优异的选择性和收率制造内酰胺化合物的方法,本发明的内酰胺制造方法,其特征在于,包括在由下述化学式1表示的催化剂和碱存在下将3-取代的二唑酮化合物进行酰胺化而制造内酰胺化合物的步骤:
[化学式1]
在上述化学式1中,
M为铱、铑、钌或钴,
X为卤素,
R1至R5彼此独立地为氢或(C1-C20)烷基,
R6为卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,
n为0至6的整数。
[化学式2]
[化学式3]
在上述化学式2和3中,
Ra1和Ra2彼此独立地为氢、(C1-C20)烷基、(C6-C20)芳基或(C3-C20)杂环烷基,
Ra3至Ra6彼此独立地为氢、卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C2-C20)烯基、(C2-C20)炔基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环或脂环族环,
q为1或2的整数。
[化学式4]
[化学式5]
在上述化学式4和5中,
Ra1和Ra2彼此独立地为氢、(C1-C20)烷基、(C6-C20)芳基或(C3-C20)杂环烷基,
Ra7至Ra10彼此独立地为氢、卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C2-C20)烯基、(C2-C20)炔基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环或脂环族环,
q为1或2的整数。
[化学式6]
[化学式7]
在上述化学式6和7中,
Ra1和Ra2彼此独立地为氢、(C1-C20)烷基、(C6-C20)芳基或(C3-C20)杂环烷基,
Ra7至Ra10彼此独立地为氢、卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C2-C20)烯基、(C2-C20)炔基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环或脂环族环,
q为1或2的整数。
[化学式8]
[化学式9]
在上述化学式8和9中,
Ra11至Ra14彼此独立地为氢或(C1-C20)烷基,
Ra15为卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C2-C20)烯基、(C2-C20)炔基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,
Ra16为氢或(C1-C20)烷基,
q为0至4的整数。
优选地,根据本发明的一实施例的碱可以为选自NaBArF 4(Sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate,四[3,5-二(三氟甲基)苯基]硼酸钠)、AgSbF6(Silver hexafluoroantimonate(V),六氟锑酸银)、AgNTf2(Silver bis(trifluoromethanesulfonyl)imide,双(三氟甲烷磺酰基)酰亚胺银)、AgBF4(Silvertetrafluoroborate,四氟硼酸银)、AgPF6(Silver hexafluorophosphate,六氟磷酸银)、AgOTf(Silver trifluoromethanesulfonate,三氟甲烷磺酸银)和AgOAc(Silver acetate,醋酸银)中的一种或两种以上,相对于上述3-取代的二唑酮化合物1摩尔可以以0.01至0.1摩尔使用。
优选地,根据本发明的一实施例的酰胺化可以在20至80℃实行。
在为了具有进一步提高选择性和收率的层面,优选地,在根据本发明的一实施例的化学式1中,M为铱,X为氯,R1至R5彼此独立地为(C1-C20)烷基,R6为卤素,n可以为0至2的整数。
优选地,在根据本发明的内酰胺化合物的制造方法的一实施例的化学式2和3中,Ra1和Ra2彼此独立地为氢、(C6-C20)芳基或邻苯二甲酰亚胺基,Ra3至Ra6彼此独立地为氢、卤素、(C1-C20)烷基、卤代(C1-C20)烷基或(C1-C20)烷氧基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环,q可以为1至2的整数。
优选地,在根据本发明的内酰胺化合物的制造方法的一实施例的化学式4至7中,Ra1和Ra2彼此独立地为氢或邻苯二甲酰亚胺基,Ra7至Ra10彼此独立地为氢、卤素、(C1-C20)烷基或(C1-C20)烷氧基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环,q可以为1至2的整数。
优选地,在根据本发明的内酰胺化合物的制造方法的一实施例的化学式8和9中,Ra11至Ra14彼此独立地为氢,Ra15为卤素、(C1-C20)烷基或(C1-C20)烷氧基,Ra16为氢或(C1-C20)烷基,p可以为0或1的整数。
另外,本发明提供根据本发明的内酰胺化合物的制造方法制造的由上述化学式3、化学式5、化学式7或化学式9表示的内酰胺化合物。
本发明的内酰胺化合物的制造方法通过在具有特定配体的特定的催化剂存在下使用具有特定官能团的起始物质,从而可以以高选择性和收率容易地制造高纯度的内酰胺化合物,并且由其制造的内酰胺化合物能够有用地用作多种领域的原材料、中间体等。
具体实施方式
本说明书中记载的“烷基”、“烷氧基”和包含“烷基”的取代基是指碳原子数1至20的直链或支链形态的烃基团。
本说明书中记载的“烯基”是由包含一个以上的双键的烃衍生的有机基团,
在本说明书中,“炔基”是由包含一个以上的三键的烃衍生的有机基团。
本说明书中记载的“卤代烷基”是指上述烷基的一个以上的氢被一个以上的卤素取代的基团,可以优选为氟。
本说明书中记载的“芳基”是通过除去一个氢而由芳香族烃衍生的有机基团,包括在各环适当包含4至7个,优选为5或6个环原子的单环或稠环系,甚至包括多个芳基通过单键连接的形态。作为具体例,有苯基、萘基、联苯基、三联苯基、蒽基、茚基、芴基、菲基、三亚苯基、芘基、苝基、基、并四苯基、荧蒽基等。上述萘基包含1-萘基和2-萘基,蒽基包含1-蒽基、2-蒽基和9-蒽基,芴基将1-芴基、2-芴基、3-芴基、4-芴基和9-芴基全部包含在内。
本说明书中记载的“杂芳基”是指包含选自B、N、O、S、P(=O)、Si和P中的1至4个的杂原子作为芳香族环骨架原子且其余芳香族环骨架原子为碳的芳基基团,是五至六元单环杂芳基、以及与一个以上的苯环稠合的多环杂芳基,可以部分饱和。此外,本发明中的杂芳基也包含一个以上的杂芳基以单键连接的形态。
本说明书中记载的“杂环烷基”是指包含选自B、N、O、S、P(=O)、Si和P中的1至4个的杂原子的具有3至20个碳原子的非芳香族单环(monocyclic)或多(multicyclic)环系,本发明的邻苯二甲酰亚胺基(phthalimido)也包括在其中。
本说明书中记载的“含稠环的芳香族环或脂环族环”的稠环可以为芳香族环或脂环族环,可以优选为芳香族环或脂环族环,具体可以为C6-C12的芳香族环或C1-C12的脂环族环,但并不限定于此。
另外,本说明书中记载的“(C1-C20)烷”基优选为(C1-C10)烷基,更优选为(C1-C7)烷基,“(C6-C20)芳”基优选为(C6-C12)芳基,“(C3-C20)杂芳”基优选为(C3-C12)杂芳基,“(C3-C20)杂环烷”基优选为(C3-C12)杂环烷基。
[化学式1]
在上述化学式1中,
M为铱、铑、钌或钴,
X为卤素,
R1至R5彼此独立地为氢或(C1-C20)烷基,
R6为卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,
n为0至6的整数。
本发明的内酰胺化合物的制造方法用除了由上述化学式1表示的催化剂以外的催化剂无法制造内酰胺化合物,通过使用由上述化学式1表示的催化剂,从而可以在温和的条件下以高选择性和收率得到内酰胺化合物。
即,本发明的内酰胺化合物的制造方法通过导入作为特定起始物质的3-取代的二唑酮化合物作为起始物质来代替现有的作为起始物质使用的羰基氮烯(carbonylnitrenes),与不稳定的羰基氮烯不同,可以容易地制造内酰胺,进而可以在温和的条件下以高选择性制造内酰胺化合物。
[化学式2]
[化学式3]
在上述化学式2和3中,
Ra1和Ra2彼此独立地为氢、(C1-C20)烷基、(C6-C20)芳基或(C3-C20)杂环烷基,
Ra3至Ra6彼此独立地为氢、卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C2-C20)烯基、(C2-C20)炔基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环或脂环族环,
q为1或2的整数。
[化学式4]
[化学式5]
在上述化学式4和5中,
Ra1和Ra2彼此独立地为氢、(C1-C20)烷基、(C6-C20)芳基或(C3-C20)杂环烷基;
Ra7至Ra10彼此独立地为氢、卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C2-C20)烯基、(C2-C20)炔基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环或脂环族环;
q为1或2的整数。
[化学式6]
[化学式7]
在上述化学式6和7中,
Ra1和Ra2彼此独立地为氢、(C1-C20)烷基、(C6-C20)芳基或(C3-C20)杂环烷基,
Ra7至Ra10彼此独立地为氢、卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C2-C20)烯基、(C2-C20)炔基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环或脂环族环,
q为1或2的整数。
[化学式8]
[化学式9]
在上述化学式8和9中,
Ra11至Ra14彼此独立地为氢或(C1-C20)烷基,
Ra15为卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C2-C20)烯基、(C2-C20)炔基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,
Ra16为氢或(C1-C20)烷基,
p为0至4的整数。
优选地,根据本发明的内酰胺化合物的制造方法的一实施例的碱可以为选自NaBArF 4(Sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate,四[3,5-二(三氟甲基)苯基]硼酸钠)、AgSbF6(Silver hexafluoroantimonate(V),六氟锑酸银)、AgNTf2(Silver bis(trifluoromethanesulfonyl)imide,双(三氟甲烷磺酰基)酰亚胺银)、AgBF4(Silver tetrafluoroborate,四氟硼酸银)、AgPF6(Silver hexafluorophosphate,六氟磷酸银)、AgOTf(Silver trifluoromethanesulfonate,三氟甲烷磺酸银)和AgOAc(Silveracetate,醋酸银)中的一种或两种以上,可以优选为选自NaBArF4(Sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate,四[3,5-二(三氟甲基)苯基]硼酸钠)、AgSbF6、AgNTf2和AgBF4中的一种或两种以上,相对于上述3-取代的二唑酮化合物1摩尔可以以0.01至0.1摩尔使用,可以优选为以0.03至0.07摩尔使用。
优选地,根据本发明的一实施例的酰胺化可以在20至80℃,优选在40至80℃搅拌8至24小时,优选搅拌8至18小时而实施。
在根据本发明的一实施例的内酰胺化合物的制造方法中,酰胺化可以在有机溶剂下进行,只要可以溶解上述反应物质,就没有必要限定有机溶剂。根据本发明的一实施例的上述有机溶剂,具体可以使用选自1,1,1,3,3,3-六氟-2-丙醇(1,1,1,3,3,3-Hexafluoro-2-propanol)、二氯甲烷(dichloromethane)、二氯乙烷(dichloroethane)、硝基甲烷(nitromethane)、甲苯(toluene)、苯(benzene)中的一种以上,考虑反应物的溶解性和去除的容易性,可以使用选自二氯甲烷(dichloromethane)、二氯乙烷和1,1,1,3,3,3-六氟-2-丙醇中的一种以上作为溶剂。
在为了以高选择性和收率制造内酰胺化合物的层面,优选地,在根据本发明的内酰胺化合物的制造方法的一实施例中,M为铱,X为氯,R1至R5彼此独立地为(C1-C20)烷基,R6为卤素,n可以为0至2的整数,在根据一实施例的化学式2和3中,Ra1和Ra2彼此独立地为氢、(C6-C20)芳基或邻苯二甲酰亚胺基,Ra3至Ra6彼此独立地为氢、卤素、(C1-C20)烷基、卤代(C1-C20)烷基或(C1-C20)烷氧基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环,q可以为1至2的整数,在根据一实施例的化学式4至7中,Ra1和Ra2彼此独立地为氢或邻苯二甲酰亚胺基,Ra7至Ra10彼此独立地为氢、卤素、(C1-C20)烷基或(C1-C20)烷氧基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环,q可以为1至2的整数,在根据一实施例的化学式8和9中,Ra11至Ra14彼此独立地为氢,Ra15为卤素、(C1-C20)烷基或(C1-C20)烷氧基,Ra16为氢或(C1-C20)烷基,p可以0或1的整数。
另外,本发明提供由上述化学式3、化学式5、化学式7或化学式9表示的内酰胺化合物。
[化学式3]
[化学式5]
[化学式7]
[化学式9]
在上述化学式3、化学式5、化学式7或化学式9中,
Ra1和Ra2彼此独立地为氢、(C1-C20)烷基、(C6-C20)芳基或(C3-C20)杂环烷基,
Ra3至Ra6彼此独立地为氢、卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C2-C20)烯基、(C2-C20)炔基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环或脂环族环,
Ra7至Ra10彼此独立地为氢、卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C2-C20)烯基、(C2-C20)炔基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环或脂环族环,
Ra11至Ra14彼此独立地为氢或(C1-C20)烷基,
Ra15为卤素、(C1-C20)烷基、卤代(C1-C20)烷基、(C2-C20)烯基、(C2-C20)炔基、(C1-C20)烷氧基、(C6-C20)芳基或(C3-C20)杂芳基,
Ra16为氢或(C1-C20)烷基,
p为0至4的整数,
q为1或2的整数。
下面,通过实施例进一步具体地说明本发明的构成,但下述的实施例是为了帮助对于本发明的理解,本发明的范围并不限定于此。
实施例I:催化剂的制造
[实施例1]催化剂A的制造
在小瓶中,添加[IrCp*Cl2]2(Cp*:pentamethylcyclopenta dienyl,五甲基环戊二烯基)(0.20g,0.25mmol)、喹啉8-醇(quinolin-8-ol)(72.6mg,0.50mmol)、碳酸钠(sodium carbonate)(0.21g,2.0mmol)和丙酮(acetone)(10mL),在室温搅拌12小时。反应结束时用硅藻土过滤(二氯甲烷(dichloromethane)(15mL×3)),进行减压蒸馏去除溶剂后,用柱色谱法(正己烷/丙酮(n-hexane/acetone)=2:1~1:1)进行分离纯化,从而制造了催化剂A。
8-羟基喹啉键合Cp*-铱配合物(8-Hydroxyquinoline bound Cp*-iridiumcomplex)(催化剂A)
橙色固体(Orange solid)(0.20g,80%);1H NMR(600Hz,CDCl3)δ8.54(d,J=4.9Hz,1H),8.03(d,J=8.3Hz,1H),7.36(t,J=7.9Hz,1H),7.30(dd,J=8.3,4.9Hz,1H),7.00(d,J=7.9Hz,1H),6.78(d,J=7.9Hz,1H),1.73(s,15H);13C NMR(150MHz,CDCl3)δ169.1,146.0,145.8,137.7,131.0,130.7,121.9,115.6,110.9,84.8(Cp*),8.9(Cp*);IR(cm-1)1564,1455,1367,1320,1111,826,751,512;HRMS(EI)m/z C19H21ClIrNO[M]+计算值(calcd.):507.0941,实测值(found):507.0943。
[实施例2]催化剂B的制造
使用5,7-二氯喹啉-8-醇(5,7-Dichloroquinolin-8-ol)(0.50mmol)代替喹啉8-醇(quinolin-8-ol),除此以外,通过与上述实施例1相同的方法制造了催化剂B。
5,7-二氯喹啉-8-醇键合Cp*-铱配合物(5,7-Dichloroquinolin-8-ol bound Cp*-iridium complex)(催化剂B)
黄色固体(Yellow solid)(0.19g,67%);1H NMR(800MHz,CD2Cl2)δ8.62(dd,J=5.0,1.3Hz,1H),8.37(dd,J=8.6,1.3Hz,1H),7.57(s,1H),7.50(dd,J=8.6,4.9Hz,1H),1.69(s,15H);13C NMR(200MHz,CD2Cl2)δ164.5,148.2,146.7,135.6,130.5,127.6,123.5,118.9,113.1,85.9,9.1;IR(cm-1)2920,1441,1368,1193,974,745,656;HRMS(EI)m/z C19H19Cl3IrNO[M]+计算值:575.0161,实测值:575.0164。
[比较例1]催化剂C的制造
在小瓶中,添加[IrCp*Cl2]2(Cp*:pentamethylcyclopentadienyl,五甲基环戊二烯基)(0.4106g,0.5154mmol)、2-(2'-吡啶基)-2-丙醇(2-(2'-pyridyl)-2-propanol)(0.1420g,1.036mmol)、碳酸氢钠(sodiumbicarbonate)(0.345g,4.11mmol)和丙酮(acetone)(50mL),在室温搅拌2小时。反应结束时用硅藻土过滤(二氯甲烷(dichloromethane)(15mL×3)),进行减压蒸馏去除溶剂后,用柱色谱法(正己烷/丙酮(n-hexane/acetone)=2:1~1:1)进行分离纯化,从而制造了催化剂C。
2-(2'-吡啶基)-2-丙醇键合Cp*-铱配合物(2-(2'-pyridyl)-2-propanolbou ndCp*-iridium complex)(催化剂C)
黄色固体(Yellow solid)(0.416g,81%);1H NMR(400MHz,MeOD)δ8.69(dt,J=5.2,1.3Hz,1H),7.88(td,J=7.9,1.5Hz,1H),7.467.31(m,2H),1.67(s,15H),1.46(s,6H);13C NMR(150MHz,MeOD)δ177.34,150.97,139.53,125.54,122.95,85.97,84.74,33.67,9.01。
[比较例2]催化剂D的制造
在小瓶中,添加[IrCp*Cl2]2(Cp*:pentamethylcyclopentadienyl,五甲基环戊二烯基)(0.20g,0.25mmol)、8-[N-(N,N-二甲基氨基羰基)氨基]喹啉(8-[N-(N,N-Dimethylaminocarbonyl)amino]quinoline)(0.50mmol)、碳酸钠(sodium carbonate)(0.16g,1.50mmol)、以及二氯甲烷(dichloromethane)(10mL),在室温搅拌12小时。反应结束时用硅藻土过滤(二氯甲烷(dichloromethane)(15mL×3)),进行减压蒸馏去除溶剂后,用柱色谱法(正己烷/丙酮(n-hexane/acetone)=2:1~1:1)进行分离纯化,从而得到了催化剂D。
8-[N-(N,N-二甲基氨基羰基)氨基]喹啉键合Cp*-铱配合物(8-[N-(N,N-Dimethylaminocarbonyl)amino]quinoline bound Cp*-iridiumcomplex)(催化剂D)
红色固体(Red solid)(0.15g,51%);1H NMR(400MHz,CDCl3)δ8.47(d,J=5.0Hz,1H),7.92(d,J=8.4Hz,1H),7.34-7.28(m,2H),6.93(d,J=8.0Hz,1H),6.68(d,J=7.9Hz,1H),3.17(s,6H),1.62(s,15H);13C NMR(150MHz,CDCl3,两个碳与其他碳合并(two carbons merged to others))δ166.5,154.8,147.0,145.0,137.7,130.5,129.9,121.7,115.6,111.6,86.0(Cp*),8.4(Cp*);IR(cm-1)2910,1622,1460,1358,1327,1150,811,772;HRMS(EI)m/z C22H27ClIrN3O[M]+计算值:577.1472,实测值:577.1475。
制造例I:异羟肟酸的制造
来自羧酸的异羟肟酸(Hydroxamic Acidsfrom Carboxylic Acids)的一锅(One-
Pot)合成
在干燥的四氢呋喃(tetrahydrofuran)(THF,30ml)中,添加羧酸(carboxylicacid)(10mmol),向其中添加1,1'-羰基二咪唑(1,1'-Carbo nyldiimidazole)(CDI,15mmol,1.5当量(equiv)),搅拌1小时。添加粉末状的盐酸羟胺(hydroxylaminehydrochloride)(1.39g,20mmol),搅拌16小时。反应结束后,向反应混合物中添加5%的KHSO4水溶液(30mL),用EtOAc(2×30mL)萃取。将聚集的有机层用盐水(50mL)洗涤,用MgSO4干燥后浓缩,用柱色谱法(洗脱液:正己烷/EtOAc,1:1~1:5)进行分离纯化,从而得到了所需的异羟肟酸(hydroxamic acid)化合物。
[制造例1]2-(3-甲氧基苯基)乙酰异羟肟酸(2-(3-Methoxyphenyl)acetylhydroxamic acid)的制造
从2-(3-甲氧基苯基)乙酸(2-(3-methoxyphenyl)acetic acid)(10mmol水平(scale))开始制造;白色固体(White solid)(1.42g,78%);m.p.115-117℃;1H NMR(600MHz,DMSO-d6)δ10.62(s,1H),8.81(s,1H),7.20(t,J=7.8Hz,1H),6.86-6.77(m,3H),3.73(s,3H),3.25(s,2H);13C NMR(150MHz,DMSO-d6)δ166.9,159.1,137.5,129.2,121.2,114.7,111.8,55.0,39.4;IR(cm-1)3193,3031,2895,1625,1488,1256,1047,761;HRMS(EI)m/z C9H11NO3[M]+计算值:181.0739,实测值:181.0736。
[制造例2]2-(3,4-二甲氧基苯基)乙酰异羟肟酸(2-(3,4-Dimethoxyphen yl)acetylhydroxamic acid)的制造
从2-(3,4-甲氧基苯基)乙酸(2-(3,4-dimethoxyphenyl)acetic acid)(5mmol水平)开始制造;白色固体(White solid)(0.57mg,54%);m.p.144-146℃;1H NMR(600MHz,DMSO-d6)δ10.57(s,1H),8.78(s,1H),6.88-6.85(m,2H),6.76(d,J=8.1Hz,1H),3.73(s,3H),3.71(s,3H),3.20(s,2H);13C NMR(150MHz,DMSO-d6)δ167.2,148.5,147.5,128.4,120.9,112.9,111.8,55.6,55.4,38.9;IR(cm-1)3169,3010,1631,1515,1259,1160,1019,601;HRMS(EI)m/z C10H13NO4[M]+计算值:211.0845,实测值:211.0843。
[制造例3]2-(3-甲基苯基)乙酰异羟肟酸(2-(3-Methylphenyl)acetylhydroxamic acid)的制造
从2-(3-甲基苯基)乙酸(2-(3-methylphenyl)aceticacid)(10mmol水平)开始制造;白色固体(White solid)(1.17g,71%);m.p.128-130℃;1HNMR(600MHz,DMSO-d6)δ10.63(s,1H),8.81(s,1H),7.17(t,J=7.5Hz,1H),7.07(s,1H),7.05-7.02(m,2H),3.23(s,2H),2.28(s,3H);13C NMR(150MHz,DMSO-d6,一个碳与其他碳合并(one carbon merged to others))δ167.0,137.2,135.9,129.5,128.1,127.0,126.0,21.0;IR(cm-1)3159,3004,2865,1628,1555,1049,682,542;HRMS(EI)m/z C9H11NO2[M]+计算值:165.0790,实测值:165.0788。
[制造例4]2-(3-氯苯基)乙酰异羟肟酸(2-(3-Chlorophenyl)acetylhydro xamicacid)的制造
从2-(3-氯苯基)乙酸(2-(3-chlorophenyl)aceticacid)(10mmol水平)开始制造;白色固体(White solid)(0.92g,50%);m.p.128-130℃;1H NMR(600MHz,DMSO-d6)δ10.67(s,1H),8.87(s,1H),7.36-7.26(m,3H),7.21(d,J=7.4Hz,1H),3.30(s,2H);13C NMR(150MHz,DMSO-d6)δ166.4,138.5,132.8,130.0,128.7,127.7,126.4,38.9;IR(cm-1)3174,3009,2897,1633,1538,1052,617;HRMS(EI)m/z C8H8ClNO2[M]+计算值:185.0244,实测值:185.0241。
[制造例5]3-苯丙基异羟肟酸(3-Phenylpropanyl hydroxamic acid)的制造
从3-苯基丙酸(3-phenylpropanoic acid)(5.0mmol水平)开始制造;白色固体(White solid)(0.75g,91%);m.p.87-89℃;1H NMR(600MHz,DMSO-d6)δ10.38(s,1H),8.72(s,1H),7.27(t,J=7.5Hz,2H),7.23-7.13(m,3H),2.80(t,J=7.7Hz,2H),2.25(t,J=7.7Hz,2H);13C NMR(150MHz,DMSO-d6)δ168.2,141.1,128.3,128.2,125.9,33.9,30.8;IR(cm-1)3285,2766,1604,1059,694;HRMS(FAB)m/z C9H11NO2[M+H]+计算值:166.0868,实测值:166.0869。
[制造例6]3-(2-溴苯基)丙烷基异羟肟酸(3-(2-Bromophenyl)propanylhydroxamic acid)的制造
从3-(2-溴苯基)丙酸(3-(2-bromophenyl)propanoicacid)(5.0mmol水平)开始制造;白色固体(White solid)(1.15g,85%);m.p.104-106℃;1HNMR(600MHz,DMSO-d6)δ10.42(s,1H),8.74(s,1H),7.58(d,J=7.9Hz,1H),7.34-7.28(m,2H),7.21-7.11(m,1H),2.91(t,J=7.7Hz,2H),2.27(t,J=7.7Hz,2H);13C NMR(150MHz,DMSO-d6)δ167.8,140.0,132.5,130.5,128.3,127.9,123.6,32.1,31.2;IR(cm-1)3160,3041,1618,1024,743;HRMS(FAB)m/z C9H10BrNO2[M+H]+计算值:243.9973,实测值:243.9975。
[制造例7]3-(3,4-二甲氧基苯基)丙酰基异羟肟酸(3-(3,4-Dimethoxyphenyl)propanoylhydroxamic acid)的制造
从3-(3,4-二甲氧基苯基)丙酸(3-(3,4-dimethoxyphenyl)propanoic acid)(10mmol水平)开始制造;白色固体(White solid)(1.14g,50%);m.p.105-107℃;1H NMR(600MHz,DMSO-d6)δ10.35(s,1H),8.69(s,1H),6.83(d,J=8.1Hz,1H),6.79(s,1H),6.69(d,J=8.1Hz,1H),3.73(s,3H),3.70(s,3H),2.74(t,J=7.7Hz,2H),2.23(t,J=7.7Hz,2H);13C NMR(150MHz,DMSO-d6)δ168.3,148.6,147.1,133.5,119.9,112.2,111.9,55.5,55.4,34.2,30.5;IR(cm-1)3191,3003,2909,1631,1512,1144,553;HRMS(EI)m/z C11H15NO4[M]+计算值:225.1001,实测值:225.1003。
在二氯甲烷(dichloromethane)(50mL)中,溶解异羟肟酸(hydroxamic acid)化合物(5.0mmol),在室温下,向其中一次性添加1,1′(0.81g,5.0mmol)搅拌30分钟。反应结束后,用1N的HCl(30mL)猝灭,用二氯甲烷(dichloromethane)萃取(50mL×3),用硫酸镁干燥,在减压下去除溶剂。将残留物用二氧化硅过滤,用二氯甲烷(dichloromethane)(10mL×2)洗涤后,减压蒸馏滤液,从而得到了目标化合物。
除了起始物质不同以外,通过与上述相同的方法制造了下述的化合物。
以2mmol水平制造;白色固体(White solid)(331mg,92%);m.p.44-46℃;1H NMR(400MHz,CDCl3)δ7.33-7.27(m,1H),6.91-6.86(m,2H),6.83-6.81(m,1H),3.89(s,2H),3.82(s,3H);13C NMR(100MHz,CDCl3)δ165.4,160.3,154.0,131.9,130.4,121.3,114.9,113.9,55.5,31.4;IR(cm-1)3079,3011,2842,1810,1348,1147,986,745;HRMS(EI)m/z C10H9NO4[M]+计算值:207.0532,实测值:207.0532。
以2mmol水平制造;白色固体(White solid)(421mg,89%);m.p.73-75℃;1H NMR(400MHz,CDCl3)δ6.88-6.82(m,2H),6.79-6.76(m,1H),3.89(s,3H),3.88(s,3H),3.87(s,2H);13C NMR(150MHz,CDCl3)δ165.6,154.1,149.7,149.4,122.7,121.6,112.1,111.9,56.2,56.1,31.0;IR(cm-1)3001,2929,2845,1821,1511,1142,987;HRMS(EI)m/z C11H11NO5[M]+计算值:237.0637,实测值:237.0639。
以2mmol水平制造;无色液体(Colorless liquid)(353mg,93%);1H NMR(400MHz,CDCl3)δ7.3(t,J=7.6Hz,1H),7.16(d,J=7.6Hz,1H),7.12-7.04(m,2H),3.87(s,2H),2.36(s,3H);13C NMR(100MHz,CDCl3)δ165.5,154.1,139.2,130.4,129.8,129.3,129.2,126.1,31.2,21.4;IR(cm-1)3022,2922,1824,1349,1143,981,744;HRMS(EI)m/z C10H9NO3[M]+计算值:191.0582,实测值:191.0581。
以1mmol水平制造;白色固体(White solid)(187mg,88%);m.p.49-51℃;1H NMR(600MHz,CDCl3)δ7.37-7.29(m,3H),7.19(d,J=6.8Hz,1H),3.92(s,2H);13C NMR(150MHz,CDCl3)δ164.8,153.8,135.2,132.3,130.6,129.3,128.9,127.3,30.9;IR(cm-1)3064,2921,1865,1831,1245,993,721;HRMS(EI)m/z C9H6ClNO3[M]+计算值:211.0036,实测值:211.0035。
以2.0mmol水平制造;白色固体(White solid)(0.36g,95%);m.p.38-40℃;1H NMR(600MHz,CDCl3)δ7.33(t,J=7.4Hz,2H),7.29-7.23(m,1H),7.19(d,J=7.4Hz,2H),3.03(t,J=7.7Hz,2H),2.94(t,J=7.7Hz,2H);13C NMR(150MHz,CDCl3)δ166.0,154.1,138.1,129.0,128.3,127.3,30.6,26.8;IR(cm-1)1815,1636,1149,980,694;HRMS(FAB)m/z C10H9NO3[M+H]+计算值:192.0661,实测值:192.0663。
以5.0mmol水平制造;白色固体(White solid)(1.04g,85%);m.p.71-73℃;1H NMR(600MHz,CDCl3)δ7.6(d,J=8.0Hz,1H),7.28(t,J=7.4Hz,1H),7.25(t,J=6.9Hz,1H),7.15(t,J=7.4Hz,1H),3.16(t,J=7.7Hz,2H),2.98(t,J=7.7Hz,2H);13C NMR(150MHz,CDCl3)δ165.7,154.1,137.5,133.4,130.6,129.2,128.1,124.3,31.3,25.2;IR(cm-1)1862,1831,1632,1150,755;HRMS(FAB)m/z C10H8BrNO3[M+H]+计算值:269.9766,实测值:269.9763。
以2mmol水平制造;白色固体(White solid)(409mg,82%);m.p.59-61℃;1H NMR(600MHz,CDCl3)δ6.82(d,J=8.1Hz,1H),6.74(d,J=8.1Hz,1H),6.70(s,1H),3.87(s,3H),3.86(s,3H),2.98(t,J=7.1Hz,2H),2.92(t,J=7.1Hz,2H);13C NMR(150MHz,CDCl3)δ166.0,154.1,149.3,148.3,130.6,120.3,111.7,111.6,56.1,56.0,30.3,27.1;IR(cm-1)2962,2936,2838,1821,1512,1134,754;HRMS(EI)m/z C12H13NO5[M]+计算值:251.0794,实测值:251.0795。
以2mmol水平制造;白色固体(White solid)(420mg,95%);m.p.39-41℃;1H NMR(600MHz,CDCl3)δ7.12(d,J=8.6Hz,2H),6.86(d,J=8.6Hz,2H),3.80(s,3H),2.98(t,J=7.4Hz,2H),2.90(t,J=7.4Hz,2H);13C NMR(150MHz,CDCl3)δ166.0,158.8,154.2,130.1,129.4,114.5,55.4,29.8,27.1;IR(cm-1)3000,2914,2834,1828,1512,1222,750;HRMS(EI)m/z C11H11NO4[M]+计算值:221.0688,实测值:221.0690。
以2mmol水平制造;白色固体(White solid)(0.20g,50%);m.p.77-79℃;1H NMR(600MHz,CDCl3)δ7.07(d,J=8.4Hz,2H),6.79(d,J=8.4Hz,2H),4.84(br,1H),2.97(t,J=7.5Hz,2H),2.90(t,J=7.5Hz,2H);13C NMR(150MHz,CDCl3)δ166.0,154.8,154.2,130.3,129.6,115.9,29.9,27.1;IR(cm-1)3454,2918,1810,1513,1166,985,825;HRMS(EI)m/z C10H9NO4[M]+计算值:207.0532,实测值:207.0529。
以2mmol水平制造;白色固体(White solid)(0.19g,41%);m.p.96-98℃;1H NMR(600MHz,CDCl3)δ6.87(d,J=8.0Hz,1H),6.73-6.64(m,2H),5.55(s,1H),3.88(s,3H),2.99-2.95(m,2H),2.94-2.88(m,2H);13C NMR(150MHz,CDCl3)δ166.0,154.2,146.8,144.9,130.0,121.0,114.9,110.9,56.1,30.4,27.2;IR(cm-1)3471,1827,1510,1257,981,817;HRMS(EI)m/z C11H11NO5[M]+计算值:237.0637,实测值:237.0635。
以1mmol水平制造;白色固体(White solid)(0.07g,24%);m.p.71-73℃;1H NMR(400MHz,CDCl3)δ7.32(s,1H),7.05(d,J=8.3Hz,1H),6.97(d,J=8.3Hz,1H),5.51(s,1H),3.45-2.01(m,4H);13C NMR(150MHz,CDCl3)δ165.7,154.0,151.6,131.8,131.7,129.2,116.6,110.6,29.4,26.9;IR(cm-1)3344,1816,1649,1419,1169,985,769;HRMS(EI)m/z C10H8BrNO4[M]+计算值:284.9637,实测值:284.9639。
以1mmol水平制造;无色油(Colorless oil)(0.05g,22%);1H NMR(600MHz,CDCl3)δ6.93(d,J=8.1Hz,1H),6.40(s,1H),6.34(d,J=8.1Hz,1H),3.77(s,3H),2.92(t,J=7.2Hz,2H),2.85(t,J=7.2Hz,2H);13C NMR(150MHz,CDCl3)δ166.6,158.6,156.4,154.6,130.7,118.5,107.1,99.2,55.4,25.8,25.5;IR(cm-1)3333,2938,1817,1596,1288,1151,831;HRMS(EI)m/z C11H11NO5[M]+计算值:237.0637,实测值:237.0639。
[制造例20]3-(4-羟基-3,5-二甲基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxy-3,5-dimethylphenethyl)-1,4,2-dioxazol-5-one)的制造
以1mmol水平制造;白色固体(White solid)(0.08g,36%);m.p.100-102℃;1H NMR(600MHz,CDCl3)δ6.81(s,2H),4.65(s,1H),2.93-2.85(m,4H),2.23(s,6H);13C NMR(150MHz,CDCl3)δ166.2,154.3,151.4,129.7,128.4,123.6,29.9,27.1,16.0;IR(cm-1)3459,2942,1861,1418,1202,1149,984;HRMS(EI)m/z C12H13NO4[M]+计算值:235.0845,实测值:235.0843。
[制造例21]2-{2-(4-羟基苯基)-1-(5-氧代-1,4,2-二唑-3-基)乙基}异吲哚啉-1,3-二酮(2-{2-(4-Hydroxyphenyl)-1-(5-oxo-1,4,2-dioxazol-3-yl)eth yl}isoindoline-1,3-dione)的制造
以1mmol水平制造;白色固体(White solid)(0.11g,31%);m.p.153-155℃;1H NMR(600MHz,CDCl3)δ7.85-7.79(m,2H),7.79-7.70(m,2H),7.05(d,J=8.2Hz,2H),6.68(d,J=8.2Hz,2H),5.54(dd,J=10.2,5.6Hz,1H),3.63-3.40(m,2H);13C NMR(150MHz,CDCl3)δ166.8,163.8,155.2,153.4,134.9,131.2,130.5,126.4,124.1,115.9,46.7,33.1;IR(cm-1)3371,1855,1705,1387,1310,991,711;HRMS(EI)m/zC18H12N2O6[M]+计算值:352.0695,实测值:352.0699。
以1mmol水平制造;白色固体(White solid)(0.05g,22%);m.p.59-61℃;1H NMR(600MHz,CDCl3)δ7.00(d,J=8.3Hz,1H),6.44(d,J=8.3Hz,1H),6.34(s,1H),5.57(br,1H),3.76(s,3H),2.97(t,J=6.7Hz,2H),2.92(t,J=6.7Hz,2H);13C NMR(150MHz,CDCl3)δ166.6,160.0,154.7,154.5,131.2,117.2,106.1,102.4,55.5,25.5,25.4;IR(cm-1)3417,2951,1823,1521,1212,1113,978;HRMS(EI)m/z C11H11NO5[M]+计算值:237.0637,实测值:237.0640。
[制造例23]3-{2-(2-羟基萘-1-基)乙基}-1,4,2-二唑-5-酮(3-{2-(2-Hydroxynaphthalen-1-yl)ethyl}-1,4,2-dioxazol-5-one)的制造
以1mmol水平制造;黄色树脂(Yellow resin)(0.07g,27%);1HNMR(600MHz,CDCl3)δ7.84(d,J=8.6Hz,1H),7.81(d,J=8.1Hz,1H),7.69(d,J=8.8Hz,1H),7.54(t,J=7.7Hz,1H),7.37(t,J=7.5Hz,1H),7.03(d,J=8.8Hz,1H),5.47(br,1H),3.49(t,J=7.4Hz,2H),2.99(t,J=7.4Hz,2H);13C NMR(150MHz,CDCl3)δ166.6,154.5,151.1,132.8,129.6,129.3,129.2,127.4,123.6,121.8,117.8,116.4,24.8,20.4;IR(cm-1)3394,3065,1823,1627,1513,1276,988,745;HRMS(EI)m/z C14H11NO4[M]+计算值:257.0688,实测值:257.0689。
以2mmol水平制造;无色油(Colorless oil)(0.22g,56%);1H NMR(600MHz,CDCl3)δ7.15(d,J=8.3Hz,2H),6.83(d,J=8.3Hz,2H),5.34(br,1H),3.85(s,2H);13C NMR(150MHz,CDCl3)δ165.7,155.9,154.2,130.5,122.5,116.3,30.6;IR(cm-1)3413,1818,1513,1215,1145,983,756;HRMS(EI)m/z C9H7NO4[M]+计算值:193.0375,实测值:193.0371。
[制造例25]3-{2-(4-甲氧基-1H-吲哚-3-基)乙基}-1,4,2-二唑-5-酮(3-{2-(4-Methoxy-1H-indol-3-yl)ethyl}-1,4,2-dioxazol-5-one)的制造
以1mmol水平制造;浅黄色固体(Pale yellow solid)(0.05g,26%);m.p.131-133℃;1H NMR(600MHz,CDCl3)δ7.98(br,1H),7.12(t,J=8.0Hz,1H),6.98(d,J=7.9Hz,1H),6.90(s,1H),6.52(d,J=7.6Hz,1H),3.94(s,3H),3.26(t,J=6.9Hz,2H),3.05(t,J=6.9Hz,2H);13C NMR(150MHz,CDCl3)δ166.9,154.6,154.5,138.3,123.5,121.0,116.9,113.4,104.8,99.8,55.3,27.4,22.8;IR(cm-1)3414,2926,1812,1507,1079,981,734;HRMS(EI)m/z C13H12N2O4[M]+计算值:260.0797,实测值:260.0794。
[制造例26]3-{2-(1-甲基-1H-吲哚-3-基)乙基}-1,4,2-二唑-5-酮(3-{2-(1-Methyl-1H-indol-3-yl)ethyl}-1,4,2-dioxazol-5-one)的制造
以1mmol水平制造;棕色固体(Brown solid)(0.12g,48%);m.p.78-80℃;1H NMR(600MHz,CDCl3)δ7.55(d,J=8.0Hz,1H),7.32(d,J=8.2Hz,1H),7.29-7.24(m,1H),7.15(t,J=7.5Hz,1H),6.91(s,1H),3.76(s,3H),3.20(t,J=7.5Hz,2H),3.01(t,J=7.5Hz,2H);13C NMR(150MHz,CDCl3)δ166.4,154.3,137.2,127.2,126.8,122.2,119.4,118.4,111.1,109.7,32.8,26.2,20.6;IR(cm-1)2926,1825,1412,1328,1154,976,753;HRMS(EI)m/z C13H12N2O3[M]+计算值:244.0848,实测值:244.0849。
以2mmol水平制造;白色固体(White solid)(0.40g,97%);m.p.35-37℃;1H NMR(600MHz,CDCl3)δ7.14(d,J=7.8Hz,2H),7.09(d,J=7.8Hz,2H),3.00(t,J=7.6Hz,2H),2.92(t,J=7.6Hz,2H),2.34(s,3H);13C NMR(150MHz,CDCl3)δ166.0,154.2,136.9,135.1,129.7,128.2,30.2,26.9,21.2;IR(cm-1)2924,1861,1815,1629,1337,1147,984,788;HRMS(EI)m/z C11H11NO3[M]+计算值:205.0739,实测值:205.0738。
以2mmol水平制造;黄色油(Yellow oil)(0.50g,98%);1H NMR(600MHz,CDCl3)δ7.31(d,J=8.3Hz,2H),7.14(d,J=8.3Hz,2H),3.02(t,J=7.6Hz,2H),2.93(t,J=7.6Hz,2H);13C NMR(150MHz,CDCl3)δ165.7,154.0,136.5,133.3,129.7,129.3,29.9,26.7;IR(cm-1)1866,1823,1635,1491,1091,978,758;HRMS(EI)m/z C10H8ClNO3[M]+计算值:225.0193,实测值:225.0192。
以2mmol水平制造;黄色油(Yellow oil)(0.32g,61%);1H NMR(600MHz,CDCl3)δ7.60(d,J=7.9Hz,2H),7.34(d,J=7.9Hz,2H),3.11(t,J=7.7Hz,2H),2.98(t,J=7.7Hz,2H);13C NMR(150MHz,CDCl3)δ165.6,154.0,142.1,129.8(q,J=33.0Hz),128.8,126.1,124.2(q,J=271.9Hz),30.2,26.4;19F NMR(564MHz,CDCl3)δ-62.6;IR(cm-1)1868,1825,1321,1107,979,825,760;HRMS(EI)m/z C11H8F3NO3[M]+计算值:259.0456,实测值:259.0454。
[制造例30]3-{2-(4-甲氧基苯基)-2-苯基乙基}-1,4,2-二唑-5-酮(3-{2-(4-Methoxyphenyl)-2-phenylethyl}-1,4,2-dioxazol-5-one)的制造
以1mmol水平制造;黄色油(Yellow oil)(0.28g,97%);1H NMR(600MHz,CDCl3)δ7.33(appt,J=7.4Hz,2H),7.28-7.20(m,3H),7.16(d,J=8.4Hz,2H),6.86(d,J=8.4Hz,2H),4.43(t,J=8.2Hz,1H),3.78(s,3H),3.33(d,J=8.2Hz,2H);13CNMR(150MHz,CDCl3)δ165.2,158.9,154.0,141.8,133.4,129.4,129.1,128.6,127.5,114.5,55.4,46.1,31.5;IR(cm-1)2935,2836,1823,1510,1246,979,698;HRMS(EI)m/zC17H15NO4[M]+计算值:297.1001,实测值:297.1004。
以2mmol水平制造;白色固体(White solid)(0.38g,92%);m.p.86-88℃;1H NMR(600MHz,CDCl3)δ7.22-7.06(m,4H),3.04(t,J=7.8Hz,2H),2.90(t,J=7.8Hz,2H),2.34(s,3H);13C NMR(150MHz,CDCl3)δ166.1,154.2,136.4,136.0,130.9,128.6,127.5,126.7,28.1,25.6,19.3;IR(cm-1)3011,1831,1605,1388,1151,984,742;HRMS(EI)m/z C11H11NO3[M]+计算值:205.0739,实测值:205.0739。
以2mmol水平制造;白色固体(White solid)(0.29g,43%);m.p.170-172℃;1H NMR(600MHz,CDCl3)δ7.40-7.23(m,15H),4.00(s,2H);13C NMR(150MHz,CDCl3)δ165.0,153.7,144.8,128.8,128.4,127.1,56.3,37.0;IR(cm-1)3056,1818,1366,1149,977,697;HRMS(EI)m/z C22H17NO3[M]+计算值:343.1208,实测值:343.1212。
以2mmol水平制造;白色固体(White solid)(0.20g,42%);m.p.78-80℃;1H NMR(600MHz,CDCl3)δ7.98-7.93(m,1H),7.93-7.88(m,1H),7.83-7.75(m,1H),7.58(t,J=7.2Hz,1H),7.53(t,J=7.2Hz,1H),7.43(t,J=7.6Hz,1H),7.39-7.32(m,1H),3.50(t,J=7.9Hz,2H),3.07(t,J=7.9Hz,2H);13C NMR(150MHz,CDCl3,一个碳与其他碳合并(one carbon merged to others))δ166.1,154.1,134.2,131.3,129.4,128.3,126.8,126.5,126.1,125.7,122.8,28.0,26.1;IR(cm-1)3045,1828,1633,1317,1154,986,761;HRMS(EI)m/z C14H11NO3[M]+计算值:241.0739,实测值:241.0739。
以1mmol水平制造;白色固体(White solid)(0.20g,96%);1H NMR(600MHz,CDCl3)δ7.21(d,J=8.6Hz,2H),6.91(d,J=8.6Hz,2H),3.87(s,2H),3.81(s,3H);13C NMR(150MHz,CDCl3)δ165.7,159.8,154.1,130.3,122.3,114.8,55.5,30.6。
以2mmol水平制造;白色固体(White solid)(0.43g,97%);m.p.35-37℃;1H NMR(600MHz,CDCl3)δ7.25(t,J=7.3Hz,1H),6.84-6.76(m,2H),6.74(s,1H),3.80(s,3H),3.00(t,J=7.7Hz,2H),2.93(t,J=7.7Hz,2H);13C NMR(150MHz,CDCl3)δ166.0,160.1,154.1,139.7,130.1,120.6,114.3,112.5,55.4,30.6,26.7;IR(cm-1)2940,1826,1583,1257,1151,982,782,693;HRMS(EI)m/z C11H11NO4[M]+计算值:221.0688,实测值:221.0686。
以2mmol水平制造;无色油(Colorless oil)(0.51g,95%);1H NMR(600MHz,CDCl3)δ7.41(d,J=8.0Hz,1H),7.37(s,1H),7.21(t,J=7.8Hz,1H),7.14(d,J=7.6Hz,1H),3.02(t,J=7.6Hz,2H),2.98-2.90(t,J=7.6Hz,2H);13C NMR(150MHz,CDCl3)δ165.6,154.0,140.4,131.5,130.6,130.5,127.0,123.1,30.1,26.6;IR(cm-1)1866,1823,1634,1145,978,757,684;HRMS(EI)m/z C10H8BrNO3[M]+计算值:268.9688,实测值:268.9690。
在氩气氛下,在干透的小瓶中添加铱催化剂(催化剂A,2.6mg,5.0mol%)、四[3,5-双(三氟甲基)苯基]硼酸钠(sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate)(NaBArF 4,4.43mg,5.0mol%)和六氟-2-丙醇(hexafluoro-2-propanol)(HFP)或二氯甲烷(dichloromethane)(1.2mL),搅拌1分钟后,添加3-取代的二唑酮化合物(0.1mmol),在氩气氛下密封小瓶。之后将反应混合物在60℃剧烈搅拌12小时后冷却至室温,用硅藻土过滤,用二氯甲烷(dichloromethane)(10mL×4)洗涤后,在减压下浓缩。将浓缩的残留物用柱色谱法(洗脱液:正己烷/10%甲醇-EtOAc溶液,2:1~1:1或正己烷/EtOAc,2:1~1:2)进行分离纯化,从而得到了需要的内酰胺化合物。
[实施例3]5-甲氧基二氢吲哚-2-酮(5-Methoxyindolin-2-one)(1-A)/7-甲氧基二氢吲哚-2-酮(7-Methoxyindolin-2-one)(1-B)的制造
主要异构体(Major isomer)(5-甲氧基二氢吲哚-2-酮(5-Methoxyindolin-2-one)(1-A)):白色固体(White solid);1H NMR(600MHz,CDCl3)δ7.90(s,1H),6.85(s,1H),6.80-6.72(m,2H),3.78(s,3H),3.52(s,2H);13C NMR(150MHz,CDCl3)δ177.1,155.9,135.9,126.8,112.7,112.0,110.0,56.0,36.7。
次要异构体(Minor isomer)(7-甲氧基二氢吲哚-2-酮(7-Methoxyindolin-2-one)(1-B)):白色固体(White solid);1H NMR(600MHz,CDCl3)δ7.64(s,1H),6.98(t,J=7.9Hz,1H),6.85(d,J=7.4Hz,1H),6.81(d,J=8.2Hz,1H),3.87(s,3H),3.55(s,2H);13CNMR(150MHz,CDCl3)δ176.4,143.8,131.3,126.1,122.9,117.1,110.3,55.8,36.8。
[实施例4]5,6-二甲氧基二氢吲哚-2-酮(5,6-Dimethoxyindolin-2-one)(2)的制造
作为溶剂使用HFP(1.2mL)。白色固体(White solid)(18mg,93%),1H NMR(600MHz,CDCl3)δ8.60(s,1H),6.84(s,1H),6.54(s,1H),3.86(s,3H),3.84(s,3H),3.50(s,2H);13C NMR(100MHz,CDCl3)δ178.5,149.5,145.1,136.2,116.0,109.8,95.8,57.0,56.4,36.6。
[实施例5]5-甲基二氢吲哚-2-酮(5-Methylindolin-2-one)(3-A)/7-甲基二氢吲哚-2-酮(7-methylindolin-2-one)(3-B)的制造
作为溶剂使用HFP(1.2mL)。白色固体(White solid)(8mg,55%),以3.0:1的比例得到了两种异构体的混合物,并且从区域异构体混合的混合物的1H NMR决定了区域选择性(Regioselectivity)。
主要异构体(Major isomer)(5-甲基二氢吲哚-2-酮(5-Methylindolin-2-one)(3-A)):1H NMR(600MHz,CDCl3)δ8.09(s,1H),7.12-6.98(m,2H),6.76(d,J=7.8Hz,1H),3.50(s,2H),2.32(s,3H);13C NMR(150MHz,CDCl3)δ177.9,140.1,132.0,128.3,125.6,125.5,109.5,36.4,21.2。
次要异构体(Minor isomer)(7-甲基二氢吲哚-2-酮(7-methylindolin-2-one)(3-B)):1H NMR(600MHz,CDCl3)δ8.55(s,1H),7.12-6.98(m,2H),6.94(t,J=7.5Hz,1H),3.56(s,2H),2.28(s,3H);13C NMR(150MHz,CDCl3)δ178.4,141.6,129.3,125.0,122.4,122.1,119.4,36.8,16.6。
[实施例6]5-氯二氢吲哚-2-酮(5-Chloroindolin-2-one)(4-A)/7-氯二氢吲哚-2-酮(7-Chloroindolin-2-one)(4-B)的制造
主要异构体(Major isomer)(5-氯二氢吲哚-2-酮(5-Chloroindolin-2-one)(4-A)):白色固体(White solid);1H NMR(600MHz,CDCl3)δ8.31(s,1H),7.23-7.19(m,2H),6.80(d,J=8.1Hz,1H),3.54(s,2H);13C NMR(150MHz,CDCl3)δ176.9,141.0,128.1,127.9,127.0,125.3,110.6,36.3。
次要异构体(Minor isomer)(7-氯二氢吲哚-2-酮(7-Chloroindolin-2-one)(4-B)):白色固体(White solid);1H NMR(400MHz,CDCl3)δ7.87(s,1H),7.21(d,J=8.6Hz,1H),7.12(d,J=6.8Hz,1H),6.97(t,J=7.8Hz,1H),3.62(s,2H);13C NMR(150MHz,CDCl3)δ175.5,140.0,127.8,126.4,123.2,122.9,114.7,36.9。
[实施例7]6,7-二甲氧基-3,4-二氢喹啉-2(1H)-酮(6,7-Dimethoxy-3,4-dihydroquinolin-2(1H)-one)(5)的制造
作为溶剂使用HFP(1.2mL)。白色固体(White solid)(20mg,96%);1H NMR(600MHz,CDCl3)δ9.01(s,1H),6.67(s,1H),6.41(s,1H),3.85(s,3H),3.84(s,3H),2.88(t,J=7.6Hz,2H),2.61(t,J=7.6Hz,2H);13C NMR(150MHz,CDCl3)δ172.1,148.6,144.9,130.8,115.0,111.8,100.6,56.5,56.3,31.1,25.2。
在氩气氛下,在干透的小瓶中,添加铱催化剂(催化剂B,2.9mg,5.0mol%)、四[3,5-双(三氟甲基)苯基]硼酸钠(sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate)(4.43mg,5.0mol%)和六氟-2-丙醇(hexafluoro-2-propanol)(1.2mL),搅拌1分钟后,添加3-取代的二唑酮化合物(0.1mmol),在氩气氛下密封小瓶。之后将反应混合物在60℃剧烈搅拌12小时后冷却至室温,用硅藻土过滤,用二氯甲烷(dichloromethane)(10mL×4)洗涤后,在减压下浓缩。将浓缩的残留物用柱色谱法(洗脱液:正己烷/10%甲醇-EtOAc溶液,2:1~1:1或正己烷/EtOAc,2:1~1:2)进行分离纯化,从而得到了需要的内酰胺化合物。
[实施例8]6-甲氧基-3,4-二氢喹啉-2(1H)-酮(6-Methoxy-3,4-dihydroquinolin-2(1H)-one)(6)的制造
白色固体(White solid)(18mg,99%);m.p.140-142℃;1HNMR(600MHz,CDCl3)δ9.08(s,1H),6.76(d,J=8.1Hz,1H),6.73-6.68(m,2H),3.77(s,3H),2.93(t,J=7.5Hz,2H),2.61(t,J=7.5Hz,2H);13C NMR(150MHz,CDCl3)δ171.8,155.7,131.0,125.1,116.4,114.0,112.6,55.7,30.8,25.8;IR(cm-1)3191,3054,2934,1660,1499,1240,793;HRMS(EI)m/z C10H11NO2[M]+计算值:177.0790,实测值:177.0791。
[实施例9]3,4-二氢喹啉-2(1H)-酮(3,4-Dihydroquinolin-2(1H)-one)(7)的制造
白色固体(White solid)(14mg,95%);1H NMR(600MHz,CDCl3)δ9.08(s,1H),7.21-7.09(m,2H),6.98(t,J=7.3Hz,1H),6.84(d,J=7.7Hz,1H),2.97(t,J=7.5Hz,2H),2.65(t,J=7.5Hz,2H);13C NMR(150MHz,CDCl3)δ172.3,137.4,128.0,127.7,123.8,123.2,115.6,30.9,25.5。
[实施例10]6-甲基-3,4-二氢喹啉-2(1H)-酮(6-Methyl-3,4-dihydroquin olin-2(1H)-one)(8)的制造
白色固体(White solid)(14mg,88%);m.p.128-130℃;1HNMR(600MHz,CDCl3)δ8.86(s,1H),7.08-6.87(m,2H),6.72(d,J=8.3Hz,1H),2.92(t,J=7.5Hz,2H),2.62(t,J=7.5Hz,2H),2.29(s,3H);13C NMR(150MHz,CDCl3)δ172.1,134.9,132.8,128.7,128.1,123.7,115.5,30.9,25.5,20.9;IR(cm-1)3189,3051,2918,1667,1504,1373,812;HRMS(EI)m/z C10H11NO[M]+计算值:161.0841,实测值:161.0838。
[实施例11]6-氯-3,4-二氢喹啉-2(1H)-酮(6-Chloro-3,4-dihydroquinolin-2(1H)-one)(9)的制造
白色固体(White solid)(17mg,94%);m.p.158-160℃;1HNMR(600MHz,CDCl3)δ9.25(s,1H),7.19-7.08(m,2H),6.77(d,J=8.0Hz,1H),2.95(t,J=7.6Hz,2H),2.63(t,J=7.6Hz,2H);13C NMR(150MHz,CDCl3)δ172.0,136.1,128.2,128.1,127.6,125.4,116.8,30.5,25.4;IR(cm-1)3193,3051,2895,1669,1406,1186,808;HRMS(EI)m/z C9H8ClNO[M]+计算值:181.0294,实测值:181.0298。
[实施例12]6-甲氧基-4-苯基-3,4-二氢喹啉-2(1H)-酮(6-Methoxy-4-ph enyl-3,4-dihydroquinolin-2(1H)-one)(10)的制造
白色固体(White solid)(25mg,99%);m.p.122-124℃;1HNMR(600MHz,CDCl3)δ9.55(s,1H),7.32(t,J=7.5Hz,2H),7.28-7.21(m,1H),7.18(d,J=7.3Hz,2H),6.85(d,J=8.6Hz,1H),6.72(d,J=8.6Hz,1H),6.46(s,1H),4.24(t,J=7.3Hz,1H),3.67(s,3H),2.98-2.83(m,2H);13C NMR(150MHz,CDCl3)δ170.9,155.9,141.5,130.9,129.1,128.2,127.9,127.4,116.8,114.5,112.9,55.6,42.4,38.5;IR(cm-1)3208,3082,1681,1492,1258,1096,701;HRMS(EI)m/z C16H15NO2[M]+计算值:253.1103,实测值:253.1099。
[实施例13]5-甲基-3,4-二氢喹啉-2(1H)-酮(5-Methyl-3,4-dihydroquin olin-2(1H)-one)(11-A)/8-甲基-3,4-二氢喹啉-2(1H)-酮(8-Methyl-3,4-di hydroquinolin-2(1H)-one)(11-B)的制造
主要异构体(Major isomer)(5-甲基-3,4-二氢喹啉-2(1H)-酮(5-Methyl-3,4-dihydroquinolin-2(1H)-one)(11-A)):白色固体(White solid);m.p.160-162℃;1H NMR(600MHz,CDCl3)δ8.18(s,1H),7.07(t,J=7.6Hz,1H),6.87(d,J=7.5Hz,1H),6.63(d,J=7.8Hz,1H),2.91(t,J=7.6Hz,2H),2.64(t,J=7.6Hz,2H),2.29(s,3H);13C NMR(150MHz,CDCl3)δ171.5,137.3,136.3,127.3,125.2,122.2,113.5,30.5,22.1,19.5;IR(cm-1)3140,2915,1672,1390,1218,766;HRMS(EI)m/z C10H11NO[M]+计算值:161.0841,实测值:161.0843。
次要异构体(Minor isomer)(8-甲基-3,4-二氢喹啉-2(1H)-酮(8-Methyl-3,4-dihydroquinolin-2(1H)-one)(11-B)):白色固体(White solid);m.p.132-134℃;1H NMR(600MHz,CDCl3)δ7.58(s,1H),7.08-7.00(m,2H),6.91(t,J=7.5Hz,1H),2.96(t,J=7.5Hz,2H),2.63(t,J=7.5Hz,2H),2.23(s,3H);13C NMR(150MHz,CDCl3)δ171.6,135.6,129.2,126.0,123.8,122.9,122.8,30.9,25.8,16.8;IR(cm-1)3233,2848,1659,1381,1191,729;HRMS(EI)m/z C10H11NO[M]+计算值:161.0841,实测值:161.0839。
[实施例14]4,4-二苯基-3,4-二氢喹啉-2(1H)-酮(4,4-Diphenyl-3,4-dihydroquinolin-2(1H)-one)(12)的制造
白色固体(White solid)(29mg,97%);m.p.253-255℃;1H NMR(600MHz,CDCl3)δ8.40(s,1H),7.43-7.17(m,7H),7.11-7.02(m,4H),6.99(t,J=7.5Hz,1H),6.89-6.78(m,2H),3.40(s,2H);13C NMR(150MHz,CDCl3)δ170.3,143.8,137.1,131.4,129.6,128.7,128.5,128.3,127.2,123.2,116.3,52.0,44.6;IR(cm-1)3065,2911,1674,1485,1372,757,697;HRMS(EI)m/z C21H17NO[M]+计算值:299.1310,实测值:299.1313。
[实施例15]3,4-二氢苯并[h]喹啉-2(1H)-酮(3,4-Dihydrobenzo[h]quino lin-2(1H)-one)(13)的制造
棕色固体(Brown solid)(18mg,93%);m.p.193-195℃;1H NMR(600MHz,CDCl3)δ8.94(s,1H),7.93(d,J=8.5Hz,1H),7.84(d,J=8.1Hz,1H),7.59-7.51(m,2H),7.49(t,J=7.5Hz,1H),7.30(d,J=8.2Hz,1H),3.13(t,J=7.6Hz,2H),2.78(t,J=7.6Hz,2H);13C NMR(150MHz,CDCl3)δ172.1,133.2,132.1,128.8,126.6,126.2,125.9,123.1,122.5,119.6,119.4,31.1,26.1;IR(cm-1)3216,2928,1660,1469,1392,816,758;HRMS(EI)m/z C13H11NO[M]+计算值:197.0841,实测值:197.0842。
[实施例16]8-溴-3,4-二氢喹啉-2(1H)-酮(8-Bromo-3,4-dihydroquinolin-2(1H)-one)(14)的制造
白色固体(White solid)(17mg,75%);m.p.77-79℃;1H NMR(600MHz,CDCl3)δ7.80(s,1H),7.40(d,J=8.1Hz,1H),7.12(d,J=7.3Hz,1H),6.87(t,J=7.7Hz,1H),2.99(t,J=7.5Hz,2H),2.64(t,J=7.5Hz,2H);13C NMR(150MHz,CDCl3)δ170.7,135.3,131.0,127.3,125.7,123.9,109.8,30.8,26.1;IR(cm-1)3185,2915,1674,1467,1193,743;HRMS(EI)m/z C9H8BrNO[M]+计算值:224.9789,实测值:224.9786。
[实施例17]5-甲氧基二氢吲哚-2-酮(5-Methoxyindolin-2-one)(15)的制造
白色固体(White solid)(9mg,56%);1H NMR(600MHz,CD2Cl2)δ8.15(s,1H),6.86(s,1H),6.79(d,J=8.4Hz,1H),6.75(d,J=8.4Hz,1H),3.77(s,3H),3.50(s,2H);13C NMR(150MHz,CDCl3)δ176.7,155.6,136.0,126.8,112.3,111.7,109.6,55.6,36.5。
[实施例18]6-甲氧基-3,4-二氢喹啉-2(1H)-酮(6-Methoxy-3,4-dihydroquinolin-2(1H)-one)(16-A)/8-甲氧基-3,4-二氢喹啉-2(1H)-酮(8-Methox y-3,4-dihydroquinolin-2(1H)-one)(16-B)的制造
主要异构体(Major isomer)(6-甲氧基-3,4-二氢喹啉-2(1H)-酮(6-Methoxy-3,4-dihydroquinolin-2(1H)-one)(16-A)):白色固体(White solid);m.p.140-142℃;1HNMR(600MHz,CDCl3)δ9.08(s,1H),6.76(d,J=8.1Hz,1H),6.73-6.68(m,2H),3.77(s,3H),2.93(t,J=7.5Hz,2H),2.61(t,J=7.5Hz,2H);13C NMR(150MHz,CDCl3)δ171.8,155.7,131.0,125.1,116.4,114.0,112.6,55.7,30.8,25.8;IR(cm-1)3191,3054,2934,1660,1499,1240,793;HRMS(EI)m/z C10H11NO2[M]+计算值:177.0790,实测值:177.0791。
次要异构体(Minor isomer)(8-甲氧基-3,4-二氢喹啉-2(1H)-酮(8-Methoxy-3,4-dihydroquinolin-2(1H)-one)(16-B)):白色固体(White solid);m.p.96-98℃;1H NMR(400MHz,CDCl3)δ7.78(s,1H),6.94(t,J=7.9Hz,1H),6.84-6.62(m,2H),3.86(s,3H),2.96(t,J=7.6Hz,2H),2.64(t,J=7.6Hz,2H);13C NMR(100MHz,CDCl3)δ170.5,145.9,126.6,124.1,122.8,120.1,109.1,55.9,30.8,25.5;IR(cm-1)3204,2953,1666,1377,1261,1092,760;HRMS(EI)m/z C10H11NO2[M]+计算值:177.0790,实测值:177.0788。
[实施例19]6-溴-3,4-二氢喹啉-2(1H)-酮(6-Bromo-3,4-dihydroquinolin-2(1H)-one)(17-A)/8-溴-3,4-二氢喹啉-2(1H)-酮(8-Bromo-3,4-dihydro quinolin-2(1H)-one)(17-B)的制造
主要异构体(Major isomer)(6-溴-3,4-二氢喹啉-2(1H)-酮(6-Bromo-3,4-dihydroquinolin-2(1H)-one)(17-A)):白色固体(White solid);m.p.156-158℃;1H NMR(600MHz,CDCl3)δ8.41(s,1H),7.33-7.27(m,2H),6.67(d,J=8.3Hz,1H),2.95(t,J=7.5Hz,2H),2.59(t,J=7.5Hz,2H);13C NMR(150MHz,CDCl3)δ171.3,136.5,131.0,130.6,125.9,116.9,115.6,30.5,25.3;IR(cm-1)3050,2895,1669,1487,1250,811,542;HRMS(EI)m/z C9H8BrNO[M]+计算值:224.9789,实测值:224.9787。
次要异构体(Minor isomer)(8-溴-3,4-二氢喹啉-2(1H)-酮(8-Bromo-3,4-dihydroquinolin-2(1H)-one)(17-B)):白色固体(White solid);m.p.77-79℃;1H NMR(600MHz,CDCl3)δ7.80(s,1H),7.40(d,J=8.1Hz,1H),7.12(d,J=7.3Hz,1H),6.87(t,J=7.7Hz,1H),2.99(t,J=7.5Hz,2H),2.64(t,J=7.5Hz,2H);13C NMR(150MHz,CDCl3)δ170.7,135.3,131.0,127.3,125.7,123.9,109.8,30.8,26.1;IR(cm-1)3185,2915,1674,1467,1193,743;HRMS(EI)m/z C9H8BrNO[M]+计算值:224.9789,实测值:224.9786。
[实施例20]1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(1-Azaspiro[4.5]deca-6,9-diene-2,8-dione)(18)的制造
在氩气氛下,在干透的小瓶中添加铱催化剂(催化剂B,2.9mg,5.0mol%)、四[3,5-双(三氟甲基)苯基]硼酸钠(sodium tetrakis[3,5-bis(trifluor omethyl)phenyl]borate)(4.43mg,5.0mol%)和六氟-2-丙醇(hexafluoro-2-propanol)(1.2mL),搅拌1分钟后,添加3-(4-羟基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxyphenethyl)-1,4,2-dioxazol-5-one)(0.1mmol),在氩气氛下密封小瓶。之后将反应混合物在60℃剧烈搅拌12小时后冷却至室温,用硅藻土过滤,用二氯甲烷(dichloromethane)(10mL×4)洗涤后,在减压下浓缩。将浓缩的残留物用柱色谱法(洗脱液:正己烷/EtOAc,2:1~1:2)进行分离纯化,从而得到了1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(1-Azaspiro[4.5]deca-6,9-diene-2,8-dione)(18)。
1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(1-Azaspiro[4.5]deca-6,9-diene-2,8-dione)(18)
白色固体(White solid)(16mg,98%);m.p.166-158℃;1HNMR(600MHz,丙酮-d6)δ7.04(d,J=9.7Hz,2H),6.12(d,J=9.7Hz,2H),2.45(t,J=8.0Hz,2H),2.27(t,J=8.0Hz,2H);13C NMR(150MHz,丙酮-d6,一个碳与其他碳合并(one carbonmerged to others))δ185.0,177.0,151.8,128.5,57.9,32.8;IR(cm-1)3246,1696,1618,1247,859,682;HRMS(EI)m/z C9H9NO2[M]+计算值:163.0633,实测值:163.0633。
[实施例21]7-甲氧基-1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(7-Methoxy-1-azaspiro[4.5]deca-6,9-diene-2,8-dione)(19)的制造
作为起始物质使用3-(4-羟基-3-甲氧基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxy-3-methoxyphenethyl)-1,4,2-dioxazol-5-one)(0.1mmol)代替3-(4-羟基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxyphenethyl)-1,4,2-dioxazo l-5-one),除此以外,通过与上述实施例20相同的方法进行反应,从而制造了7-甲氧基-1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(7-Methoxy-1-azaspir o[4.5]deca-6,9-diene-2,8-dione)(19)。
白色固体(White solid)(19mg,99%);m.p.221-223℃;1HNMR(600MHz,CDCl3)δ6.84(d,J=9.9Hz,1H),6.23(d,J=10.8Hz,1H),6.16(s,1H),5.71(s,1H),3.68(s,3H),2.60-2.52(m,2H),2.38-2.24(m,2H);13C NMR(150MHz,CDCl3)δ180.0,177.1,150.8,150.0,127.9,116.7,59.1,55.2,33.6,29.7;IR(cm-1)3301,1671,1640,1395,1209,1109,864;HRMS(EI)m/z C10H11NO3[M]+计算值:193.0739,实测值:193.0739。
[实施例22]7-溴-1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(7-Bromo-1-azasp iro[4.5]deca-6,9-diene-2,8-dione)(20)的制造
作为起始物质使用3-(3-溴-4-羟基苯乙基)-1,4,2-二唑-5-酮(3-(3-Br omo-4-hydroxyphenethyl)-1,4,2-dioxazol-5-one)代替3-(4-羟基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxyphenethyl)-1,4,2-dioxazol-5-one),除此以外,通过与上述实施例20相同的方法进行反应,从而制造了7-溴-1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(7-Bromo-1-azaspiro[4.5]deca-6,9-diene-2,8-dione)(20)。
白色固体(White solid)(23mg,95%);m.p.187-189℃;1HNMR(600MHz,CDCl3)δ7.29(s,1H),6.86(d,J=9.9Hz,1H),6.70(s,1H),6.34(d,J=9.9Hz,1H),2.62-2.47(m,2H),2.37-2.25(m,2H);13C NMR(150MHz,CDCl3)δ177.5,177.2,149.7,149.6,127.3,124.9,60.3,32.1,29.3;IR(cm-1)3144,3053,2854,1667,1334,1098,798,665;HRMS(EI)m/z C9H8BrNO2[M+H]+计算值:241.9817,实测值:241.9815。
[实施例23]6-甲氧基-1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(6-Methoxy-1-azaspiro[4.5]deca-6,9-diene-2,8-dione)(21)的制造
作为起始物质使用3-(4-羟基-2-甲氧基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxy-2-methoxyphenethyl)-1,4,2-dioxazol-5-one)(0.1mmol)代替3-(4-羟基-2-甲氧基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxy-2-methoxyphe nethyl)-1,4,2-dioxazol-5-one),除此以外,通过与上述实施例20相同的方法进行反应,从而制造了6-甲氧基-1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(6-Methoxy-1-azaspiro[4.5]deca-6,9-diene-2,8-dione)(21)。
白色固体(White solid)(19mg,99%);m.p.179-181℃;1HNMR(600MHz,CDCl3)δ6.84(d,J=9.9Hz,1H),6.23(d,J=10.8Hz,1H),6.16(s,1H),5.71(s,1H),3.68(s,3H),2.60-2.52(m,2H),2.38-2.24(m,2H);13C NMR(150MHz,CDCl3)δ180.0,177.1,150.8,150.0,127.9,116.7,59.1,55.2,33.6,29.7;IR(cm-1)3144,3067,2875,1664,1224,855,511;HRMS(EI)m/z C10H11NO3[M]+计算值:193.0739,实测值:193.0741。
[实施例24]7,9-二甲基-1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(7,9-Dimet hyl-1-azaspiro[4.5]deca-6,9-diene-2,8-dione)(22)的制造
作为起始物质使用3-(4-羟基-3,5-二甲基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxy-3,5-dimethylphenethyl)-1,4,2-dioxazol-5-one)(0.1mmol)代替3-(4-羟基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxyphenethyl)-1,4,2-dio xazol-5-one),除此以外,通过与上述实施例20相同的方法进行反应,从而制造了7,9-二甲基-1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(7,9-Dimethyl-1-azaspiro[4.5]deca-6,9-diene-2,8-dione)(22)。
白色固体(White solid)(18mg,93%);m.p.183-185℃;1HNMR(600MHz,CDCl3)δ6.57(s,2H),6.52(s,1H),2.51(t,J=7.8Hz,2H),2.18(t,J=7.8Hz,2H),1.87(s,6H);13C NMR(150MHz,CDCl3)δ186.0,177.7,144.6,135.2,57.7,32.6,29.8,16.0;IR(cm-1)3194,2946,1634,1341,902,761;HRMS(EI)m/z C11H13NO2[M]+计算值:191.0946,实测值:191.0948。
[实施例25]3-(1,3-二氧异二氢吲哚-2-基)-1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(3-(1,3-Dioxoisoindolin-2-yl)-1-azaspiro[4.5]deca-6,9-diene-2,8-dion e)(23)的制造
作为起始物质使用2-{2-(4-羟基苯基)-1-(5-氧代-1,4,2-二唑-3-基)乙基}异二氢吲哚-1,3-二酮(2-{2-(4-Hydroxyphenyl)-1-(5-oxo-1,4,2-dioxazol-3-yl)ethyl}isoindoline-1,3-dione)(0.1mmol)代替3-(4-羟基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxyphenethyl)-1,4,2-dioxazol-5-one),除此以外,通过与上述实施例20相同的方法进行反应,从而制造了3-(1,3-二氧异二氢吲哚-2-基)-1-氮杂螺[4.5]癸-6,9-二烯-2,8-二酮(3-(1,3-Dioxoisoindolin-2-yl)-1-azaspiro[4.5]deca-6,9-diene-2,8-dione)(23)。
白色固体(White solid)(28mg,91%);m.p.260-262℃;1HNMR(600MHz,CDCl3)δ7.87(dd,J=5.0,2.7Hz,2H),7.77(dd,J=5.0,2.7Hz,2H),7.19-7.06(m,1H),7.06-6.88(m,1H),6.58(s,1H),6.37-6.20(m,2H),5.17(t,J=9.9Hz,1H),2.79-2.69(m,1H),2.64-2.49(m,1H);13C NMR(150MHz,CDCl3)δ184.2,171.5,167.4,149.3,148.4,134.7,131.8,129.7,128.8,123.9,54.7,48.3,35.8;IR(cm-1)3353,1703,1391,1117,860,714;HRMS(EI)m/z C17H12N2O4[M]+计算值:308.0797,实测值:308.0801。
[实施例26]8-甲氧基-1-氮杂螺[4.5]癸-6,9-二烯-2,6-二酮(8-Methoxy-1-azaspiro[4.5]deca-7,9-diene-2,6-dione)(24)的制造
作为起始物质使用3-(2-羟基-4-甲氧基苯乙基)-1,4,2-二唑-5-酮(3-(2-Hydroxy-4-methoxyphenethyl)-1,4,2-dioxazol-5-one)(0.1mmol)代替3-(4-羟基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxyphenethyl)-1,4,2-dioxazol-5-one),除此以外,通过与上述实施例20相同的方法进行反应,从而制造了8-甲氧基-1-氮杂螺[4.5]癸-6,9-二烯-2,6-二酮(8-Methoxy-1-azaspiro[4.5]deca-7,9-diene-2,6-dione)(24)。
白色固体(White solid)(19mg,99%);m.p.127-129℃;1HNMR(600MHz,CDCl3)δ6.38(d,J=10.0Hz,1H),6.19-6.07(m,2H),5.41(d,J=2.3Hz,1H),3.79(s,3H),2.75-2.58(m,1H),2.45-2.20(m,2H),2.08-1.95(m,1H);13C NMR(150MHz,CDCl3)δ199.7,179.6,170.7,143.5,123.1,97.8,64.3,56.3,32.4,28.5;IR(cm-1)3210,1673,1572,1412,1206,995,633;HRMS(EI)m/z C10H11NO3[M]+计算值:193.0739,实测值:193.0741。
[实施例27]2H-螺[萘-1,2'-吡咯烷]-2,5'-二酮(2H-Spiro[naphthalene-1,2'-pyrrolidine]-2,5'-dione)(25)的制造
作为起始物质使用3-{2-(2-羟基萘-1-基)乙基}-1,4,2-二唑-5-酮(3-{2-(2-Hydroxynaphthalen-1-yl)ethyl}-1,4,2-dioxazol-5-one)(0.1mmol)代替3-(4-羟基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxyphenethyl)-1,4,2-diox azol-5-one),除此以外,通过与上述实施例20相同的方法进行反应,从而制造了2H-螺[萘-1,2'-吡咯烷]-2,5'-二酮(2H-Spiro[naphthalene-1,2'-pyrro lidine]-2,5'-dione)(25)。
白色固体(White solid)(21mg,99%);m.p.216-218℃;1H NMR(600MHz,CDCl3)δ7.61(d,J=7.7Hz,1H),7.49-7.43(m,2H),7.40-7.33(m,2H),6.20(d,J=9.9Hz,1H),5.95(s,1H),2.59-2.49(m,2H),2.49-2.39(m,1H),2.09-1.98(m,1H);13C NMR(150MHz,CDCl3)δ200.4,179.3,145.4,143.4,131.1,130.1,129.7,128.8,125.6,123.5,68.8,36.7,28.3;IR(cm-1)3167,3070,2922,1672,1353,1086,751;HRMS(EI)m/z C13H11NO2[M]+计算值:213.0790,实测值:213.0792。
[实施例28]1-氮杂螺[3.5]壬-5,8-二烯-2,7-二酮(1-Azaspiro[3.5]nona-5,8-diene-2,7-dione)(26)的制造
作为起始物质使用3-(4-羟基苄基)-1,4,2-二唑-5-酮(3-(4-Hydroxybenzyl)-1,4,2-dioxazol-5-one)(0.1mmol)代替3-(4-羟基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxyphenethyl)-1,4,2-dioxazol-5-one),除此以外,通过与上述实施例20相同的方法进行反应,从而制造了1-氮杂螺[3.5]壬-5,8-二烯-2,7-二酮(1-Azaspiro[3.5]nona-5,8-diene-2,7-dione)(26)。
白色固体(White solid)(9mg,63%);m.p.158-160℃;1H NMR(600MHz,CDCl3)δ6.96(d,J=9.8Hz,2H),6.58-6.12(m,3H),3.26(s,2H);13C NMR(150MHz,CDCl3)δ184.6,164.9,148.2,130.8,51.0,50.1;IR(cm-1)3292,1748,1661,1617,1396,1260,866;HRMS(EI)m/z C8H7NO2[M]+计算值:149.0477,实测值:149.0475。
[实施例29]双螺二氢吲哚化合物(Di-spiroindoline compound)A(27)的制造
作为起始物质使用3-{2-(4-甲氧基-1H-吲哚-3-基)乙基}-1,4,2-二唑-5-酮(3-{2-(4-Methoxy-1H-indol-3-yl)ethyl}-1,4,2-dioxazol-5-one)(0.1mm ol)代替3-(4-羟基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxyphenethyl)-1,4,2-dioxazol-5-one),除此以外,通过与上述实施例20相同的方法进行反应,从而制造了双螺二氢吲哚化合物(Di-spiroindoline compound)A(27)。
黄色固体(Yellow solid)(12mg,56%);m.p.286-288℃;1H NMR(600MHz,CDCl3)δ6.67(t,J=8.0Hz,2H),6.07(d,J=8.2Hz,2H),5.64(d,J=7.8Hz,2H),5.59(s,2H),3.80(s,6H),2.79-2.67(m,2H),2.53-2.43(m,2H),2.43-2.36(m,2H),2.32-2.22(m,2H);13C NMR(150MHz,CDCl3)δ176.2,156.0,150.0,131.4,115.0,103.1,101.4,72.8,65.8,55.3,34.2,30.3;IR(cm-1)3272,2939,1676,1608,1365,1252,1083,728;HRMS(EI)m/z C24H24N4O4[M]+计算值:432.1798,实测值:432.1801。
[实施例30]双螺二氢吲哚化合物(Di-spiroindoline compound)B(28)的制造
作为起始物质使用3,3-{2-(1-甲基-1H-吲哚-3-基)乙基}-1,4,2-二唑-5-酮(3,3-{2-(1-Methyl-1H-indol-3-yl)ethyl}-1,4,2-dioxazol-5-one)代替3-(4-羟基苯乙基)-1,4,2-二唑-5-酮(3-(4-Hydroxyphenethyl)-1,4,2-dioxazol-5-one),除此以外,通过与上述实施例20相同的方法进行反应,从而制造了双螺二氢吲哚化合物(Di-spiroindoline compound)B(28)。
黄色固体(Yellow solid)(15mg,77%);m.p.204-206℃;1H NMR(600MHz,CDCl3)δ7.02(d,J=7.3Hz,2H),6.94(t,J=7.6Hz,2H),6.55(t,J=7.4Hz,2H),5.84(d,J=7.8Hz,2H),5.57(s,2H),2.88-2.77(m,2H),2.61-2.51(m,2H),2.50-2.41(m,2H),2.36-2.24(m,8H);13C NMR(150MHz,CDCl3)δ176.1,149.0,130.0,129.3,122.1,116.8,105.1,75.6,65.4,34.9,30.2,30.0;IR(cm-1)3053,2927,1686,1607,1343,1226,729;HRMS(EI)m/z C24H24N4O2[M]+计算值:400.1899,实测值:400.1899。
[比较例3]
在实施例3中,使用催化剂C代替催化剂A,除此以外,通过相同的方法制造了5-甲氧基吲哚啉-2-酮(5-Methoxyindolin-2-one)。
其结果,分别以5%以下得到了5-甲氧基吲哚啉-2-酮(5-Methoxyind olin-2-one)和7-甲氧基吲哚啉-2-酮(7-Methoxyindolin-2-one)。
[比较例4]
在实施例3中,使用催化剂D代替催化剂A,除此以外,通过相同的方法制造了5-甲氧基吲哚啉-2-酮(5-Methoxyindolin-2-one)。
其结果,完全没有制造出5-甲氧基吲哚啉-2-酮(5-Methoxyindolin-2-one)。
根据本发明的实施例的内酰胺化合物的制造方法通过使用特定的催化剂,从而可以制造内酰胺化合物,但使用作为具有与本发明的催化剂不同的配体的催化剂的催化剂C和催化剂D的比较例3至4没有制造出内酰胺化合物。
因此,使用特定催化剂和特定起始物质的本发明的内酰胺化合物的制造方法可以非常有用地用于内酰胺化合物的制造中。
Claims (14)
7.根据权利要求1所述的内酰胺化合物的制造方法,其中,所述碱为选自NaBArF 4、AgSbF6、AgNTf2、AgBF4、AgPF6、AgOTf和AgOAc中的一种或两种以上。
9.根据权利要求1所述的内酰胺化合物的制造方法,其中,所述酰胺化在20至80℃实施。
10.根据权利要求1所述的内酰胺化合物的制造方法,其中,在所述化学式1中,M为铱,X为氯,R1至R5彼此独立地为C1-C20烷基,R6为卤素,n为0至2的整数。
11.根据权利要求2所述的内酰胺化合物的制造方法,其中,Ra1和Ra2彼此独立地为氢、C6-C20芳基或邻苯二甲酰亚胺基,
Ra3至Ra6彼此独立地为氢、卤素、C1-C20烷基、卤代C1-C20烷基或C1-C20烷氧基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环,
q为1至2的整数。
12.根据权利要求3或4所述的内酰胺化合物的制造方法,其中,Ra1和Ra2彼此独立地为氢或邻苯二甲酰亚胺基,
Ra7至Ra10彼此独立地为氢、卤素、C1-C20烷基或C1-C20烷氧基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环,
q为1至2的整数。
13.根据权利要求5所述的内酰胺化合物的制造方法,其中,Ra11至Ra14彼此独立地为氢,
Ra15为卤素、C1-C20烷基或C1-C20烷氧基,
Ra16为氢或C1-C20烷基,
p为0或1的整数。
14.一种由下述化学式3、化学式5、化学式7或化学式9表示的内酰胺化合物:
化学式3
化学式5
化学式7
化学式9
在所述化学式3、化学式5、化学式7或化学式9中,
Ra1和Ra2彼此独立地为氢、C1-C20烷基、C6-C20芳基或C3-C20杂环烷基,
Ra3至Ra6彼此独立地为氢、卤素、C1-C20烷基、卤代C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20烷氧基、C6-C20芳基或C3-C20杂芳基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环或脂环族环,
Ra7至Ra10彼此独立地为氢、卤素、C1-C20烷基、卤代C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20烷氧基、C6-C20芳基或C3-C20杂芳基,或者可以与相邻的取代基连接而形成包含或不包含稠环的芳香族环或脂环族环,
Ra11至Ra14彼此独立地为氢或C1-C20烷基,
Ra15为卤素、C1-C20烷基、卤代C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20烷氧基、C6-C20芳基或C3-C20杂芳基,
Ra16为氢或C1-C20烷基,
p为0至4的整数,
q为1或2的整数。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180000421 | 2018-01-02 | ||
KR10-2018-0000421 | 2018-01-02 | ||
KR1020180173117A KR102214593B1 (ko) | 2018-01-02 | 2018-12-28 | 락탐 화합물의 제조방법 및 이로부터 제조된 락탐 화합물 |
KR10-2018-0173117 | 2018-12-28 | ||
PCT/KR2019/000056 WO2019135604A1 (ko) | 2018-01-02 | 2019-01-02 | 락탐 화합물의 제조방법 및 이로부터 제조된 락탐 화합물 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111587239A true CN111587239A (zh) | 2020-08-25 |
CN111587239B CN111587239B (zh) | 2024-04-02 |
Family
ID=67255126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980007242.4A Active CN111587239B (zh) | 2018-01-02 | 2019-01-02 | 内酰胺化合物的制造方法及由其制造的内酰胺化合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11046661B2 (zh) |
JP (1) | JP6957758B2 (zh) |
KR (1) | KR102214593B1 (zh) |
CN (1) | CN111587239B (zh) |
AU (1) | AU2019205884B2 (zh) |
CA (1) | CA3087526C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111566116A (zh) * | 2018-01-02 | 2020-08-21 | 基础科学研究院 | 新型金属配合物、其制造方法及利用其的γ-内酰胺化合物的制造方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3882236A (en) * | 1973-12-26 | 1975-05-06 | Lilly Co Eli | Pharmaceutical compositions containing substituted 2-oxo-indolines and the use thereof to treat anxiety and tension |
JPS58192874A (ja) * | 1982-05-04 | 1983-11-10 | Banyu Pharmaceut Co Ltd | 新規スピロイソキサゾリン誘導体 |
JPS62212363A (ja) * | 1986-03-11 | 1987-09-18 | Sumitomo Chem Co Ltd | ヒドロキサム酸化合物およびその製造法 |
CN104177298A (zh) * | 2014-09-18 | 2014-12-03 | 湘潭大学 | 4,4-二取代-4,5-二氢-1h–咪唑-5-酮、衍生物及其合成方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5376058B2 (ja) | 2010-06-30 | 2013-12-25 | 富士通株式会社 | システム制御装置、情報処理システム及び情報処理システムのデータ退避及び復元方法 |
-
2018
- 2018-12-28 KR KR1020180173117A patent/KR102214593B1/ko active IP Right Grant
-
2019
- 2019-01-02 AU AU2019205884A patent/AU2019205884B2/en active Active
- 2019-01-02 CA CA3087526A patent/CA3087526C/en active Active
- 2019-01-02 JP JP2020536784A patent/JP6957758B2/ja active Active
- 2019-01-02 US US16/959,863 patent/US11046661B2/en active Active
- 2019-01-02 CN CN201980007242.4A patent/CN111587239B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3882236A (en) * | 1973-12-26 | 1975-05-06 | Lilly Co Eli | Pharmaceutical compositions containing substituted 2-oxo-indolines and the use thereof to treat anxiety and tension |
JPS58192874A (ja) * | 1982-05-04 | 1983-11-10 | Banyu Pharmaceut Co Ltd | 新規スピロイソキサゾリン誘導体 |
JPS62212363A (ja) * | 1986-03-11 | 1987-09-18 | Sumitomo Chem Co Ltd | ヒドロキサム酸化合物およびその製造法 |
CN104177298A (zh) * | 2014-09-18 | 2014-12-03 | 湘潭大学 | 4,4-二取代-4,5-二氢-1h–咪唑-5-酮、衍生物及其合成方法 |
Non-Patent Citations (6)
Title |
---|
COLUMBUS, OHIO, US REGISTRY[ONLINE]: "STN检索报告" * |
NIKITA JAIN ET AL.: "Oxidative Amidation in the Naphthalene Series" * |
SEUNG YOUN HONG ET AL.: "Ir(III)-Catalyzed Stereoselective Haloamidation of Alkynes Enabled by Ligand Participation" * |
SEUNG YOUN HONG ET AL.: "Selective formation of g -lactams via C–H amidation enabled by tailored iridium catalysts" * |
YEONGYU HWANG ET AL.: "Revisiting Arene C(sp2)ÀH Amidation by Intramolecular Transfer of Iridium Nitrenoids: Evidence for a Spirocyclization Pathway" * |
ZHIHUI ZHANG ET AL.: "Synthesis and Catalytic Activity of Amino Acids and Metallopeptides with Catalytically Active Metallocyclic Side Chains" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111566116A (zh) * | 2018-01-02 | 2020-08-21 | 基础科学研究院 | 新型金属配合物、其制造方法及利用其的γ-内酰胺化合物的制造方法 |
CN111566116B (zh) * | 2018-01-02 | 2023-06-09 | 基础科学研究院 | 新型金属配合物、其制造方法及利用其的γ-内酰胺化合物的制造方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111587239B (zh) | 2024-04-02 |
KR102214593B1 (ko) | 2021-02-15 |
US20200331871A1 (en) | 2020-10-22 |
AU2019205884B2 (en) | 2021-04-08 |
CA3087526C (en) | 2022-12-13 |
AU2019205884A1 (en) | 2020-07-30 |
CA3087526A1 (en) | 2019-07-11 |
JP6957758B2 (ja) | 2021-11-02 |
KR20190082675A (ko) | 2019-07-10 |
JP2021509116A (ja) | 2021-03-18 |
US11046661B2 (en) | 2021-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tsang et al. | A Palladium-Catalyzed Method for the Synthesis of Carbazoles via Tandem CH Functionalization and CN Bond Formation | |
EP1564203B1 (fr) | Nouveau procédé de synthèse du (7-méthoxy-1-naphtyl)acétonitrile et application à la synthèse de l'agomélatine | |
JP2019504041A (ja) | キラルスピロビインダン骨格化合物及びその製造方法 | |
Yu et al. | Synthesis and X-ray crystallographic analysis of quinazolinone cholecystokinin/gastrin receptor ligands | |
Si et al. | One-Pot Tandem ortho-Naphthoquinone-Catalyzed Aerobic Nitrosation of N-Alkylanilines and Rh (III)-Catalyzed C–H Functionalization Sequence to Indole and Aniline Derivatives | |
KR20180088724A (ko) | 3차 아릴 아민의 제조를 위한 부흐발트-하르트비히 아릴화 방법 | |
Wu et al. | Development of highly enantioselective new Lewis basic N-formamide organocatalysts for hydrosilylation of imines with an unprecedented substrate profile | |
CN111587239A (zh) | 内酰胺化合物的制造方法及由其制造的内酰胺化合物 | |
CN110143911B (zh) | 一种N-(吲哚-N-甲酰基)-α-氨基酰胺衍生物的制备方法 | |
CN112920033A (zh) | 邻炔基苯基环丁酮的制备方法及萘酮的制备方法 | |
CN112168824B (zh) | 阿朴菲类化合物的应用 | |
US11998901B2 (en) | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | |
KR102060527B1 (ko) | 발광 특성을 가지는 4환 접합 n-헤테로고리 화합물 및 이의 제조방법 | |
CN106279013A (zh) | 一种由羧酸和胺直接催化合成酰胺的方法 | |
KR101885084B1 (ko) | N-아실 인돌 유도체의 아민화 방법 | |
KR102590897B1 (ko) | 키랄 감마-락탐 화합물의 제조방법 및 이를 위한 금속 착체 | |
Zhang et al. | Superacid-Promoted Reactions of N-Acyliminium Ions: An effective route to substituted 3-Oxo-1, 2, 3, 4-tetrahydroisoquinolines and related products | |
KR101808274B1 (ko) | 1,3-치환된 이소인돌린 유도체 및 이의 입체선택적 제조방법 | |
JPH0317076A (ja) | 6―フルオロ―4―クロマノン―2―カルボン酸アミド又はエステルの製造法 | |
KR20050083886A (ko) | 인단-1,3-디카르복실산의 제조 방법 | |
Bowman et al. | Palladium and radical routes to phenanthridines | |
Smalley Jr et al. | Regioselective synthesis of 3, 3‐diethyl‐4‐(methylene)‐1‐quinol‐2‐ones by an intramolecular microwave assisted heck reaction | |
KR101623704B1 (ko) | 신규한 플루오렌 유도체 및 이의 제조방법 | |
Weber et al. | Push-Pull Triafulvenes from 1, 1′-Oxy-di [2, 3-bis (dimethylamino) cyclopropenylium] and 1-[Bis (dimethylamino) cyclopropenylio] pyridinium Salts | |
JPH06199705A (ja) | テトラリン誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |